Scientific Opinion on Flavouring Group Evaluation 208 Revision 2 (FGE.208Rev2): Consideration of genotoxicity data on alicyclic aldehydes with α,β‐unsaturation in ring/side‐chain and precursors from chemical subgroup 2.2 of FGE.19 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Aug 03, 2018
Scientific Opinion on Flavouring Group Evaluation 208 Revision 2 (FGE.208Rev2):
Consideration of genotoxicity data on alicyclic aldehydes with ,unsaturation in
ring/sidechain and precursors from chemical subgroup 2.2 of FGE.19
Beltoft, Vibe Meister; Nørby, Karin Kristiane; EFSA Panel on Food Contact Materials
Published in:
E F S A Journal
Link to article, DOI:
10.2903/j.efsa.2017.4766
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Panel on Food Contact Materials (2017). Scientific Opinion on Flavouring Group Evaluation 208 Revision
2 (FGE.208Rev2): Consideration of genotoxicity data on alicyclic aldehydes with ,unsaturation in ring/sidechain
and precursors from chemical subgroup 2.2 of FGE.19. E F S A Journal, 15(5), [e04766]. DOI:
10.2903/j.efsa.2017.4766
SCIENTIFIC OPINION
ADOPTED: 22 March 2017
doi: 10.2903/j.efsa.2017.4766
Scientiﬁc Opinion on Flavouring Group Evaluation 208
Revision 2 (FGE.208Rev2): Consideration of genotoxicity
data on alicyclic aldehydes with a,b-unsaturation in
ring/side-chain and precursors from chemical subgroup
2.2 of FGE.19
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF),
Vittorio Silano, Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel,
Paul Fowler, Roland Franz, Konrad Grob, Trine Husøy, Sirpa K€arenlampi, Wim Mennes,
Maria Rosaria Milana, Andre Penninks, Andrew Smith, Maria de Fatima Tavares Pocas,
Christina Tlustos, Detlef W€olﬂe, Holger Zorn, Corina-Aurelia Zugravu, Mona-Lise Binderup,
Francesca Marcon, Daniel Marzin, Pasquale Mosesso, Maria Anastassiadou, Maria Carfı,
Siiri Saarma and Rainer G€urtler
Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) was
requested to evaluate the genotoxic potential of ﬂavouring substances from subgroup 2.2 of FGE.19 in the
Flavouring Group Evaluation 208 Revision 2 (FGE.208Rev2). In FGE.208Rev1, the CEF Panel evaluated
genotoxicity studies on p-mentha-1,8-dien-7-al [FL-no: 05.117], the representative substance for FGE.19
subgroup 2.2. The Comet assay performed in liver showed a positive result, and therefore, the
Panel concluded that p-mentha-1,8-dien-7-al [FL-no: 05.117] is genotoxic in vivo and that, accordingly,
there is a safety concern for its use as ﬂavouring substance. Since p-mentha-1,8-dien-7-al [FL-no: 05.117]
is representative for the nine remaining substances of subgroup 2.2 (p-mentha-1,8-dien-7-ol [FL-no:
02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], 2,6,6-trimethyl-1-cyclohexen-1-
carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272], p-mentha-1,8-dien-7-yl acetate
[FL-no: 09.278], myrtenyl acetate [FL-no: 09.302], myrtenyl-2-methylbutyrate [FL-no: 09.899] and
myrtenyl-3-methylbutyrate [FL-no: 09.900]), the Panel concluded in the previous revision of FGE.208
(FGE.208Rev1) that there is a potential safety concern for these substances. Subsequently, the industry
has submitted genotoxicity studies on ﬁve substances of FGE.19 subgroup 2.2: p-mentha-1,8-dien-7-ol
[FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], p-mentha-1,8-dien-7-yl acetate
[FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302], which are evaluated in the present revision of
FGE.208 (FGE.208Rev2). The Panel concluded that the concern for genotoxicity could be ruled out for
p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], p-mentha-1,8-dien-7-yl acetate [FL-
no: 09.278] and myrtenyl acetate [FL-no: 09.302], which will be evaluated through the Procedure.
Genotoxicity data on myrtenal [FL-no: 05.106] were considered equivocal, therefore, it cannot be
evaluated through the Procedure, presently. p-Mentha-1,8-dien-7-al [FL-no: 05.117] and four
substances not supported by industry (2,6,6-trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121],
myrtenyl formate [FL-no: 09.272], myrtenyl-2-methylbutyrate [FL-no: 09.899] and myrtenyl-3-
methylbutyrate [FL-no: 09.900]) have been deleted from the Union List.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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Keywords: FGE.19, subgroup 2.2, alicyclic aldehydes, a,b-unsaturated
EFSA Journal 2017;15(5):4766www.efsa.europa.eu/efsajournal
Requestor: European Commission
Question numbers: EFSA-Q-2015-00843, EFSA-Q-2016-00146, EFSA-Q-2016-00151, EFSA-Q-2016-00228,
EFSA-Q-2016-00277
Correspondence: ﬁp@efsa.europa.eu
Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul
Fowler, Roland Franz, Konrad Grob, Rainer G€urtler, Trine Husøy, Sirpa K€arenlampi, Wim Mennes, Maria
Rosaria Milana, Andre Penninks, Vittorio Silano, Andrew Smith, Maria de Fatima Tavares Pocas,
Christina Tlustos, Detlef W€olﬂe, Holger Zorn and Corina-Aurelia Zugravu.
Acknowledgements: The Panel wishes to thank the hearing experts: Vibe Beltoft and Karin Nørby
and EFSA staff members: Annamaria Rossi for the support provided to this scientiﬁc output.
Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings
and Processing Aids), Silano V, Bolognesi C, Castle L, Cravedi J-P, Engel K-H, Fowler P, Franz R, Grob K,
Husøy T, K€arenlampi S, Mennes W, Milana MR, Penninks A, Smith A, de Fatima Tavares Pocas M,
Tlustos C, W€olﬂe D, Zorn H, Zugravu C-A, Binderup M-L, Marcon F, Marzin D, Mosesso P, Anastassiadou
M, Carfı M, Saarma S and G€urtler R, 2017. Scientiﬁc Opinion on Flavouring Group Evaluation
208 Revision 2 (FGE.208Rev2): Consideration of genotoxicity data on alicyclic aldehydes with
a,b-unsaturation in ring/side-chain and precursors from chemical subgroup 2.2 of FGE.19. EFSA Journal
2017;15(5):4766, 44 pp. https://doi.org/10.2903/j.efsa.2017.4766
ISSN: 1831-4732
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Flavouring Group Evaluation 208 Revision 2
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2017;15(5):4766
Summary
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF) was asked to deliver a scientiﬁc opinion on the
implications for human health of chemically deﬁned ﬂavouring substances used in or on foodstuffs in
the Member States. In particular, the Panel was asked to evaluate ﬂavouring substances using the
Procedure as referred to in the Commission Regulation (EC) No 1565/2000 (hereafter ‘the Procedure’).
The Union List of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/2012. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.
The Flavouring Group Evaluation 208 (FGE.208), corresponding to subgroup 2.2 of FGE.19,
concerns three alicyclic aldehydes with the a,b-unsaturation in ring/side-chain and seven precursors for
such. The a,b-unsaturated aldehyde structure, which is a structural alert for genotoxicity and the data
on genotoxicity previously available for these 10 substances, did not rule out the concern for
genotoxicity.
Among the 10 ﬂavouring substances in FGE.19 subgroup 2.2, the Panel identiﬁed p-mentha-1,
8-dien-7-al [FL-no: 05.117], for which appropriate genotoxicity data could be used for reading across
to the other substances in the subgroup; therefore, genotoxicity data have been requested for
p-mentha-1,8-dien-7-al [FL-no: 05.117] according to the testing strategy worked out by the Panel.
In 2012, the Flavour Industry submitted new genotoxicity data: a bacterial reverse mutation assay,
a hypoxanthine-guanine phosphoribosyl transferase (HPRT) assay and an in vitro micronucleus assay.
These new data were evaluated in FGE.208 where the Panel concluded that the available data still
gave rise to concern for the genotoxic potential of p-mentha-1,8-dien-7-al [FL-no: 05.117]. Therefore,
the Panel asked to provide an in vivo Comet assay performed on the ﬁrst site of contact (e.g. stomach
or duodenum) and on liver.
The Flavour Industry submitted a combined study in rats: a bone marrow micronucleus test and
Comet assay in liver and duodenum. This study was evaluated in Revision 1 of FGE.208
(FGE.208Rev1). p-Mentha-1,8-dien-7-al [FL-no: 05.117] was administered to rats by oral gavage at
three dose levels: 175, 350 and 700 mg/kg body weight (bw) per day (which is an estimate of the
maximum tolerated dose). The results of the micronucleus assay suggest that p-mentha-1,8-dien-7-al
[FL-no: 05.117] did not induce any increase in micronucleated polychromatic erythrocytes.
In the same animals, results of the Comet assay suggest that p-mentha-1,8-dien-7-al [FL-no:
05.117] did not induce any DNA damage in duodenum, but a statistically signiﬁcant increase in DNA
strand breaks was observed in the liver at the highest dose tested (700 mg/kg bw per day).
The Panel noted that the results observed at the highest dose were more than threefold higher
than the concurrent negative control value and statistically signiﬁcant different from the negative
control value, and a statistically signiﬁcant positive linear trend was observed. The Panel considered
that since there was a wide range of historical control data with an overlap of the positive and
negative historical control values, the historical control data could not be used as a criterion to
interpret the data.
Overall, the Panel concluded that p-mentha-1,8-dien-7-al [FL-no: 05.117] is genotoxic in vivo and
that, accordingly, there is a safety concern for its use as ﬂavouring substance.
Since p-mentha-1,8-dien-7-al [FL-no: 05.117] is representative for the nine remaining substances of
this subgroup 2.2 (p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no:
05.106], 2,6,6-trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no:
09.272], p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278], myrtenyl acetate [FL-no: 09.302], myrtenyl-
2-methylbutyrate [FL-no: 09.899] and myrtenyl-3-methylbutyrate [FL-no: 09.900]), the
Panel concluded, in the previous revision of FGE.208 (FGE.208Rev1), that there is a potential safety
concern for these substances.
Subsequently, the industry has submitted in vitro genotoxicity studies on p-mentha-1,8-dien-7-ol
[FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], p-mentha-1,8-dien-7-yl acetate
[FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302], which are evaluated in the present revision of
FGE.208 (FGE.208Rev2).
The Panel considered that the newly submitted in vitro genotoxicity studies on p-mentha-1,8-dien-
7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278] and
myrtenyl acetate [FL-no: 09.302] were adequately performed and that the results were negative.
Therefore, the concern for genotoxicity could be ruled out for these ﬂavouring substances that could
be evaluated through the Procedure.
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Myrtenal [FL-no: 05.106] did not induce gene mutations in a bacterial reverse mutation assay. The
ﬁrst in vitro micronucleus assay provided was equivocal and had several weaknesses; therefore, a
repetition of the study was requested. The second study is considered more reliable than the ﬁrst one,
but the result is still not fully adequate to rule out the concern for genotoxicity. In this second study,
weak statistically signiﬁcant increases of the micronuclei frequency were observed at the lowest and
highest concentrations (without statistically signiﬁcant trend) in the absence of S9-mix after long
treatment, while after short treatment, there was a statistically signiﬁcant trend (without statistically
signiﬁcant differences between single concentrations tested and the concurrent control). The
Panel considered that also the result of this second study was equivocal and that this was not
adequately investigated by the applicant. Therefore, myrtenal cannot be evaluated through the
Procedure, presently.
The Panel also considered two recent publications on the evaluation of genotoxicity studies on
p-mentha-1,8-dien-7-al [FL-no: 05.117], which were published after the publication of the scientiﬁc
opinion on Flavouring Group Evaluation 208 Revision 1 (FGE.208Rev1). The Panel concluded that these
two publications do not give reason to modify the conclusion drawn on the genotoxicity of p-mentha-
1,8-dien-7-al [FL-no: 05.117] in FGE.208Rev1.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
On 27 July 2015, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 208 Revision 1 (FGE.208Rev1):
Consideration of genotoxicity data on representatives for 10 alicyclic aldehydes with the a,
b-unsaturation in ring/side-chain and precursors from chemical subgroup 2.2 of FGE.19.
The Panel concluded that p-mentha-1,8-dien-7-al [FL-no: 05.117] is genotoxic in vivo and as that
substance was regarded as the representative of the group, there is a potential safety concern for the
other substances in this group. Following this opinion, the Commission withdrew from the Union List of
ﬂavourings the representative substance FL-no: 05.1174 and also the non-supported substances 2,6,
6-trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272],
myrtenyl-2-methylbutyrate [FL-no: 09.899] and myrtenyl-3-methylbutyrate [FL-no: 09.900].5
On 25 November 2015, the applicant submitted an in vitro micronucleus assay and a bacterial
reverse mutation assay on the substance myrtenol [FL-no: 02.091]. It also submitted additional studies
and data on the other four remaining substances p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol
[FL-no: 02.091], myrtenal [FL-no: 05.106], p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278] and
myrtenyl acetate [FL-no: 09.302] at later stages at the beginning of 2016.
Also, following the EFSA opinion of 2015, the Commission amended the conditions of use of these
other ﬁve substances of this group in another Regulation6 and put a footnote ‘under evaluation by
EFSA’ to them in the Union List of ﬂavourings, pending the evaluation of the additional data.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate the
studies in the submissions on the following ﬁve substances of FGE.19 subgroup 2.2: p-mentha-1,
8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], p-mentha-1,8-dien-7-yl
acetate [FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302], taking into account also the uses
reported, the Commission Regulations adopted following the EFSA opinion of July 2015 and any new
other safety information relevant available, and, depending on the outcome, proceed to the full
evaluation on these ﬁve ﬂavouring substances, taking into account the requirements of the Commission
Regulation (EC) No 1565/2000 and of Regulation (EU) No 1334/2008. The authority is also asked to
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
4 Commission Regulation (EU) 2015/1760 of 1 October 2015 amending Annex I to Regulation (EC) No 1334/2008 of the
European Parliament and of the Council as regards removal from the Union list of the ﬂavouring substance p-mentha-1,8-dien-
7-al. OJ L 257, 2.10.2015, p. 27–29.
5 Commission Regulation (EU) 2016/637 of 22 April 2016 amending Annex I to Regulation (EC) No 1334/2008 of the European
Parliament and of the Council as regards removal from the Union list of certain ﬂavouring substances. OJ L 108, 23.4.2016,
p. 24–27.
6 Commission Regulation (EU) 2016/1244 of 28 July 2016 amending Annex I to Regulation (EC) No 1334/2008 of the European
Parliament and of the Council as regards certain ﬂavouring substances from a group related with an alpha beta unsaturation
structure. OJ L 204, 29.7.2016, p. 7–10.
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characterise the hazards and also quantify the exposure also in case its concern on genotoxicity cannot
be ruled out and the EFSA CEF Panel procedure cannot be applied for any of the substances of the group.
1.2. Interpretation of the Terms of Reference
This revision concerns the evaluation of p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no:
02.091], myrtenal [FL-no: 05.106], myrtenyl acetate [FL-no: 09.302] and p-mentha-1,8-dien-7-yl
acetate [FL-no: 09.278] for which industry submitted new data on genotoxicity.
During the evaluation process, the industry sent to EFSA two publications on the genotoxicity
evaluation of p-mentha-1,8-dien-7-al [FL-no: 05.117] which has been evaluated in FGE.208Rev1 and
these two recent publications are discussed in the present opinion (FGE.208Rev2).
2. Data and methodologies
2.1. History of the evaluation of FGE.19 substances
Flavouring Group Evaluation 19 (FGE.19) contains 360 ﬂavouring substances from the EU Register
being a,b-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl
substances via hydrolysis and/or oxidation (EFSA, 2008a).
The a,b-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA,
2008a). The Panel noted that there were limited genotoxicity data on these ﬂavouring substances but
that positive genotoxicity studies were identiﬁed for some substances in the group.
The a,b-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure–activity relationship (Q)SAR prediction of the genotoxicity of these substances
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE Models and
ISS-Local Models, (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed,
but considered that the outcome of these validations was not always extensive enough to appreciate
the validity of the predictions of these models for these a,b-unsaturated carbonyls. Therefore, the
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided
not to take substances through the Procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and
Netzeva, 2007a,b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the
fact that there are available data on genotoxicity, in vitro and in vivo, as well as data on
carcinogenicity for several substances. Based on these data the Panel decided that 15 subgroups
(1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008a) could
not be evaluated through the Procedure due to concern with respect to genotoxicity. Corresponding to
these subgroups, 15 FGEs were established: FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219,
221, 222, 223, 224 and 225.
For 11 subgroups, the Panel decided, based on the available genotoxicity data and (Q)SAR
predictions, that a further scrutiny of the data should take place before requesting additional data
from the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203,
210, 212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218, it was
concluded that a genotoxic potential could be ruled out and accordingly these substances were
evaluated using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201,
203, 210, 212, 213, 216, 217 and 220, the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related a,b-unsaturated substances in
the different subgroups for which additional data are requested, EFSA worked out a list of representative
substances for each subgroup (EFSA, 2008c). Likewise, an EFSA genotoxicity expert group has worked
out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b).
The Flavouring Industry has been requested to submit additional genotoxicity data according to the
list of representative substances and test strategy for each subgroup.
2.2. History of the evaluation of the substances in subgroup 2.2
Subgroup 2.2 was one of the FGE.19 subgroups for which the Panel concluded that, based on the
available data, additional genotoxicity data were necessary to perform the risk assessment for these
substances (EFSA, 2008a).
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The Panel identiﬁed one substance in subgroup 2.2 of FGE.19, p-mentha-1,8-dien-7-al [FL-no:
05.117], which represents the other nine substances in this subgroup (EFSA, 2008c). For this
substance, genotoxicity data according to the test strategy (EFSA, 2008b) have been requested. The
representative substance is shown in Table 1.
In 2012, the industry submitted new genotoxicity data: a bacterial gene mutation assay (Ames
test), a gene mutation assay in mammalian cells (hypoxanthine-guanine phosphoribosyl transferase
(HPRT) assay) and an in vitro micronucleus assay. These data were evaluated in FGE.208 (EFSA CEF
Panel, 2013), where the Panel concluded that the available data still gave rise to concern for the
genotoxic potential of p-mentha-1,8-dien-7-al [FL-no: 05.117]. Therefore, the Panel asked to provide
an in vivo Comet assay performed on the ﬁrst site of contact (e.g. stomach or duodenum) and on liver.
Revision 1 of FGE.208 (FGE.208Rev1) concerned the evaluation of a combined bone marrow
micronucleus test and Comet assay in the liver and duodenum of rats. These data have been
submitted by industry (Beevers, 2014a,b) in response to the requested genotoxicity data in FGE.208
on the representative substance for subgroup 2.2, p-mentha-1,8-dien-7-al [FL-no: 05.117]. The
Panel concluded that p-mentha-1,8-dien-7-al [FL-no: 05.117] is genotoxic in vivo and that, accordingly,
there is a safety concern for its use as ﬂavouring substance. Since p-mentha-1,8-dien-7-al [FL-no:
05.117] is representative for the nine remaining substances of this subgroup 2.2 (p-mentha-1,8-dien-
7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], 2,6,6-trimethyl-1-
cyclohexen-1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272], p-mentha-1,8-dien-7-yl
acetate [FL-no: 09.278], myrtenyl acetate [FL-no: 09.302], myrtenyl-2-methylbutyrate [FL-no: 09.899]
and myrtenyl-3-methylbutyrate [FL-no: 09.900]), the Panel concluded in revision 1 of FGE.208 that there
is a potential safety concern for these substances (EFSA CEF Panel, 2015).
p-Mentha-1,8-dien-7-al [FL-no: 05.117] and four substances not supported by industry (2,6,6-
trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272], myrtenyl-
2-methylbutyrate [FL-no: 09.899] and myrtenyl-3-methylbutyrate [FL-no: 09.900]) have been deleted
from the Union List (Commission Regulation (EU) 2015/17604, Commission Regulation (EU) 2016/6375).
FGE
Adopted by the
CEF Panel
Link
No.
Substances
FGE.208 19 March 2013 http://www.efsa.europa.eu/en/efsajournal/pub/3151.htm 10
FGE.208Rev1 24 June 2015 http://www.efsa.europa.eu/en/efsajournal/pub/4173.htm 10
FGE.208Rev2 22 March 2017 http://www.efsa.europa.eu/en/efsajournal/pub/4766.htm 5
FGE: Flavouring Group Evaluation.
Industry has submitted genotoxicity data for the ﬁve remaining substances of subgroup 2.2.
Genotoxicity studies on p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal
[FL-no: 05.106], p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302]
are evaluated in the present revision of FGE.208 (FGE.208Rev2).
Table 1: Representative substance for subgroup 2.2 of FGE.19 (EFSA, 2008c)
FL-no
JECFA-no
Subgroup EU Register name Structural formula
FEMA no
CoE no
CAS no
05.117
973
2.2 p-Mentha-1,8-dien-7-al O 3557
11788
2111-75-3
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives;
FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract Service.
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During the evaluation process, the industry sent to EFSA two publications on the genotoxicity
evaluation of p-mentha-1,8-dien-7-al [FL-no: 05.117] which has been evaluated in FGE.208Rev1 and
these two recent publications are discussed in the present opinion (FGE.208Rev2, Appendix F).
Exposure data on substances for which the concern for genotoxicity cannot be ruled out are
reported in Appendix E.
2.3. Presentation of the substances belonging to FGE.208Rev2
The Flavouring Group Evaluation 208, corresponding to subgroup 2.2 of FGE.19, concerned three
alicyclic aldehydes with a,b-unsaturation in ring/side-chain and seven precursors for such aldehydes.
The 10 substances evaluated in FGE.208 and FGE.208Rev1 are listed in Table 2.
Eight of the ﬂavouring substances have been previously evaluated by JECFA (2002a). A summary of
their current evaluation status by JECFA and the outcome of this consideration are presented in
Appendix A, Table A.1.
The a,b-unsaturated aldehyde structure is a structural alert for genotoxicity (EFSA, 2008a) and data
on genotoxicity previously available did not rule out the concern for genotoxicity for these 10
ﬂavouring substances.
In FGE.208Rev1 (EFSA CEF Panel, 2015), the Panel concluded that p-mentha-1,8-dien-7-al [FL-no:
05.117] is genotoxic in vivo and that, accordingly, there is a safety concern for the use of p-mentha-
1,8-dien-7-al [FL-no: 05.117] as a ﬂavouring substance. Since p-mentha-1,8-dien-7-al [FL-no: 05.117]
is representative for the nine remaining substances of this subgroup 2.2 (p-mentha-1,8-dien-7-ol [FL-
no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], 2,6,6-trimethyl-1-cyclohexen-1-
carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272], p-mentha-1,8-dien-7-yl acetate
[FL-no: 09.278], myrtenyl acetate [FL-no: 09.302], myrtenyl-2-methylbutyrate [FL-no: 09.899] and
myrtenyl-3-methylbutyrate [FL-no: 09.900]), the Panel concluded in revision 1 of FGE.208 that there is
a potential safety concern for these substances (EFSA CEF Panel, 2015). After publication of
FGE.208.Rev1, EFSA received information that four of these substances (2,6,6-trimethyl-1-cyclohexen-
1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no: 09.272], myrtenyl-2-methylbutyrate
[FL-no: 09.899] and myrtenyl-3-methylbutyrate [FL-no: 09.900]) are no longer supported for use as
ﬂavouring substances in the EU, and have been removed from the Union List5 (see Section 1.1.1).
Therefore, these four substances will not be further discussed in the newly added section in the
present revision of this FGE. Since new in vitro genotoxicity data have been submitted for p-mentha-
1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], p-mentha-1,8-dien-
7-yl acetate [FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302], these ﬁve substances will be
considered in the present revision of FGE.208 (FGE.208Rev2).
Sections 2.4 and 2.5 of this opinion report the same information that was presented in FGE.208
and FGE.208Rev1, respectively. Section 3 reports the evaluation of the new data submitted by
industry.
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2.4. Additional genotoxicity data evaluated by the Panel in FGE.2087
The industry has submitted additional data concerning genotoxicity studies for the representative
substance p-mentha-1,8-dien-7-al [FL-no: 05.117] for this subgroup (EFFA, 2012). The data for
p-mentha-1,8-dien-7-al are one in vitro test in bacteria and two in vitro tests in mammalian cell
systems.
2.4.1. In vitro data
2.4.1.1. Bacterial reverse mutation assay
An Ames assay was conducted in Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537
and TA102 to assess the mutagenicity of p-mentha-1,8-dien-7-al, both in the absence and in the
presence of metabolic activation by an Aroclor 1254-induced rat liver post mitochondrial fraction
(S9-mix) in three experiments (Bowen, 2011). A batch of 93.1% purity was used for the ﬁrst and
second experiment, while a batch of 91.9% purity was used for the third experiment. An initial toxicity
range ﬁnding experiment was carried out using the plate incorporation method in the presence
and absence of S9-mix for the TA100 strain only at concentrations of 1.6, 8, 40, 200, 1,000 and
5,000 lg/plate, plus negative (solvent) and positive controls. Evidence of toxicity in the form of
complete killing of the background lawn was observed at 5,000 lg/plate in the absence and presence
of S9-mix. Precipitation was also seen at this concentration. As valid mutation data were available from
ﬁve different test concentrations, the data from these treatments were considered to be acceptable for
mutation analysis as part of the ﬁrst main experiment. This study complies with Good Laboratory
Practice (GLP) and OECD Test Guideline 471 (OECD, 1997a).
In the ﬁrst experiment, treatments of all the remaining tester strains were performed in the
absence and presence of S9-mix at concentrations of 0.32, 1.6, 8, 40, 200, 1,000 and 5,000 lg/plate,
plus negative (solvent) and positive controls. Evidence of toxicity was observed in all strains in the
absence and presence of S9-mix at 5,000 lg/plate, and in some strains also at 1,000 lg/plate.
Precipitation was also seen at 5,000 lg/plate. Valid mutation data were obtained from ﬁve or six
different test concentrations in each strain. Following experiment 1 treatments, a statistically signiﬁcant
and concentration-related increase in revertant numbers was observed in strain TA98 at 200 lg/plate
(1.8-fold increase) and 1,000 lg/plate (3.2-fold increase) in the absence of S9-mix, when data were
analysed at the 1% level using Dunnett’s test.
In a second experiment, treatments of the strains assayed in experiment 1 were performed in the
absence and presence of S9-mix at 8.192, 20.48, 51.2, 128, 320, 800, 2,000 and 5,000 lg/plate.
Treatments in the presence of S9-mix were further modiﬁed by the inclusion of a pre-incubation step
(60 min). Evidence of toxicity ranging from a marked reduction in revertant numbers and/or slight
thinning of the bacterial lawn to a complete killing of the test bacteria was observed at 320, 800 and/or
2,000 lg/plate and above in most of the strains in the absence and presence of S9-mix. Precipitation
was again seen at 5,000 lg/plate, particularly in the presence of S9-mix. However, valid mutation data
were obtained from at least ﬁve test concentrations in each strain. Following experiment 2 treatments,
a statistically signiﬁcant and concentration-related increase in revertant numbers was again observed in
strain TA98 in the absence of S9-mix at 320 lg/plate (2.3-fold increase) and 800 lg /plate (2.9-fold
increase), when data were analysed at 1% level using Dunnett’s test.
Following the treatments in experiments 1 and 2, p-mentha-1,8-dien-7-al increased the frequency
of revertants in strain TA98 by at least twofold in the absence of S9-mix activation. These results were
in contrast with what had been observed for p-mentha-1,8-dien-7-al in previous Ames assays
described further below. One possible explanation for the varying pattern of behaviour was that the
material tested (93.1% purity) in experiments 1 and 2, due to impurities, gave positive results. A third
experiment was conducted in strain TA98, with a different batch of the test article (91.9% purity), but
with the same treatment conditions as in experiment 1. In the absence of S9-mix, toxicity was
observed at 5,000 lg/plate, while in the presence of S9-mix toxicity was observed at all concentrations
tested. Additionally, while precipitation was observed on all test plates at 5,000 lg/plate in
experiments 1 and 2, no precipitation was observed at this concentration in experiment 3. Following
the treatments in experiment 3, statistically signiﬁcant and concentration-related increases in revertant
numbers for strain TA98 in the absence of S9-mix were observed at 8 lg/plate and above when the
7 The data presented in Section 2.4 are cited from the ﬁrst version of FGE.208. These data are the basis for the conclusions in
FGE.208 requesting additional genotoxicity data.
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data were analysed at 1% level using Dunnett’s test. Therefore, the increases observed in strain TA98
were reproduced and are considered to be evidence of mutagenic activity in this strain. No other
statistically signiﬁcant increases in revertant numbers were observed in all other strains when the data
were analysed at the 1% level using Dunnett’s test (Appendix B, Table B.1).
2.4.1.2. Hypoxanthine-guanine phosphoribosyl transferase (HPRT) assay
To assess mutagenic potential in a mammalian system, mouse lymphoma L5178Y cells were treated
with p-mentha-1,8-dien-7-al in the absence and presence of S9-mix to study the induction of forward
mutations at the hprt locus (Lloyd, 2012). A batch of 92.5% purity was used. Across three different
experiments, treatments were carried out for 3 h in the absence of S9-mix, 3 h in the presence of
S9-mix and 24 h in the absence of S9-mix, and each treatment regime was independently repeated.
Concentrations for the main experiments were established in preliminary range ﬁnding cytotoxicity
experiments. This GLP study complies with OECD Test Guideline 476 (OECD, 1997b).
In the ﬁrst mutation experiment, cells were treated with p-mentha-1,8-dien-7-al for 3 h at 10, 20,
40, 60, 70, 80, 90 and 100 lg/mL in the absence of S9-mix and at 40, 60, 80, 100, 120, 140, 160 and
180 lg/mL in the presence of S9-mix. Per cent relative survival (% RS) decreased to 13% at 100 lg/mL
in the absence of S9-mix and to 16% at 180 lg/mL in the presence of S9-mix. Negative control mutant
frequencies were normal, and were signiﬁcantly increased by treatment with the positive control. No
signiﬁcant increases in mutation frequency were observed at any concentration analysed in the
presence or absence of S9-mix in this experiment, and no statistically signiﬁcant linear trends were
observed.
In a second experiment, cultures were treated with p-mentha-1,8-dien-7-al for 3 h at 20, 40, 50,
60, 70, 80, 90, 100 and 120 lg/mL in the absence of S9-mix and at 25, 50, 75, 100, 120, 140, 160,
170 and 180 lg/mL in the presence of S9-mix. Per cent RS decreased to 7% at 120 lg/mL in the
absence and to 10% at 180 lg/mL in the presence of S9-mix. Also, in this experiment, 24-h
treatments were carried out with p-mentha-1,8-dien-7-al in the absence of S9-mix at 4, 8, 12, 15, 18
and 21 lg/mL of p-mentha-1,8-dien-7-al. Per cent RS decreased to 9% at the highest concentration.
Negative control mutant frequencies were normal and were signiﬁcantly increased by treatment with
the positive control. In the absence and presence of S9-mix, there were no statistically signiﬁcant
increases in mutant frequency relative to control at any concentration analysed, although in the
absence of S9-mix (both 3- and 24-h treatments), there were statistically signiﬁcant linear trends.
In a third experiment, cultures were treated with p-mentha-1,8-dien-7-al for 24 h at 4, 8, 12, 14,
16, 18 and 20 lg/mL in the absence of S9-mix. Per cent RS decreased to 14% at the highest
concentration. Negative control mutant frequencies were normal, and were signiﬁcantly increased by
treatment with the positive control. There were no signiﬁcant or dose-related increases in mutant
frequency following p-mentha-1,8-dien-7-al treatments. The observations made with the 24-h
treatments in the second experiment were not reproduced at similar concentrations and extents of
toxicity and were considered not to be biologically relevant by the authors (Lloyd, 2012).
However, it is not clear why the 3-h treatment was not repeated. Overall, the results in the HPRT
assay in the absence of S9-mix should be considered, differently from the authors’ opinion, as
equivocal instead of negative, based on the statistically signiﬁcant trends in both 3- and 24-h
treatments in the second experiment (Appendix B, Table B.1).
2.4.1.3. In vitro micronucleus assays
p-Mentha-1,8-dien-7-al (94.9% purity) was assayed for the induction of chromosome damage in
mammalian cells in vitro by examining its effect on the frequency of micronuclei in cultured human
peripheral blood lymphocytes (whole blood cultures pooled from two healthy male volunteers) treated
in the absence and presence of S9-mix (Lloyd, 2009). p-Mentha-1,8-dien-7-al was added at 48 h
following culture initiation (stimulation by phytohaemagglutinin) either for 3 h in the absence or
presence of S9-mix followed by 21 h recovery, or for 24 h in the absence of S9-mix. Cytochalasin B
(6 lg/mL) was added either at the start of treatment (24-h treatment) or at the start of recovery
(following 3-h treatment) in order to block cytokinesis and generate binucleate cells for analysis. It
remained in the cultures until they were harvested 24 h after the start of treatment. A range-ﬁnding
experiment had been conducted with and without S9-mix treatment in order to provide toxicity
information (reduction in replication index, RI) that could be used as a basis for choosing a range of
concentrations to be evaluated in the main micronucleus analysis (Appendix B, Table B.1).
In the main assay, micronuclei were analysed from at least three concentrations for each treatment
condition. For 3-h treatment without S9-mix, the concentrations were 80, 100, 110 and 120 lg/mL, for
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3-h treatment with S9-mix the concentrations were 100, 120 and 140 lg/mL, and for 24-h treatment
without S9-mix the concentrations were 20, 25 and 35 lg/mL. The levels of cytotoxicity (reduction in
RI) at the top concentrations reached 58% and 45% in the 3-h treatment in the absence and
presence of S9-mix, and 58% in the 24-h treatment in the absence of S9-mix, respectively. These
levels of cytotoxicity therefore reached, or were very close to, the recommended (50–60%) range of
cytotoxicity. One thousand binucleate cells per culture from two replicate cultures per concentration
were scored for micronuclei. This GLP study complies with OECD Test Guideline 487.
The frequencies of micronucleated binucleate (MNBN) cells in negative control cultures were
normal, and were signiﬁcantly increased by treatment with positive control chemicals. Treatment of
cells with p-mentha-1,8-dien-7-al in the absence and presence of S9-mix under all treatment
conditions resulted in frequencies of MNBN cells that were similar to and not signiﬁcantly different
from those observed in concurrent vehicle controls for all concentrations analysed. The MNBN cell
frequency of all p-mentha-1,8-dien-7-al treated cultures fell within (or slightly below) normal ranges. It
was concluded that p-mentha-1,8-dien-7-al did not induce micronuclei in cultured human peripheral
blood lymphocytes when tested at toxic concentrations in both the absence and presence of S9-mix
(Lloyd, 2009).
2.4.2. Previously available data
2.4.2.1. In vitro data
Several in vitro mutagenicity/genotoxicity tests have been performed on the FGE.19 subgroup 2.2
representative substance p-mentha-1,8-dien-7-al [FL-no: 05.117]. The quality of most of them could not
be adequately evaluated, either because they are in Japanese and therefore details are difﬁcult to obtain
or because of limitations in the experimental design. Negative results were reported by Ishidate et al.
(1984) for an Ames test in which S. Typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98
were used. Duplicate plates were used for each of the six concentrations up to 1,000 lg/plate with
S9-mix. The sample used had the same purity (93.1%) of the batch used by Bowen (2011). The results
were only reported as  or + (a + would be given if revertant numbers exceeded 29 concurrent control)
and therefore weaker responses may have been observed but cannot be veriﬁed. Fujita et al. (1994) also
reported negative results for an Ames assay in strains TA97 and TA102 performed both with and without
S9-mix. The top concentration of p-mentha-1,8-dien-7-al was less than in the Ishidate study, namely
100 lg/plate. Negative results were reported in mutation tests in which p-mentha-1,8-dien-7-al was
incubated with Escherichia coli WP2 cells at 50–400 lg/plate (Yoo, 1986). Few details can be obtained
from the paper, but it appears that the maximum increase in revertants was 1.3-fold, which is considered
negative. However, only one result was given, so the test was probably only conducted in the absence of
S9-mix.
p-Mentha-1,8-dien-7-al was considered to be weakly positive in the rec-assay with Bacillus subtilis
strains M45 and H17 at a concentration of 2.5 lL p-mentha-1,8-dien-7-al/disk, probably equivalent to
2,500 lg/disk (Yoo, 1986). This study is a very short paper, with very few details. Another study using
the same strains reported negative results for p-mentha-1,8-dien-7-al at concentrations between 0.16
and 0.63 lL/plate (corresponding to 0.15 and 0.6 lg/plate) and positive results at higher
concentrations of 1.25 and 2.5 lL/plate (1.2 and 2.4 lg/plate) (Kuroda et al., 1984). It should be
noted that these DNA damage assays in bacteria do not detect mutation, are non-standard and not
requested by regulatory agencies. The results cannot therefore be considered to carry as much weight
as results from recommended, standard assays.
In a study by Eder et al. (1993), p-mentha-1,8-dien-7-al gave negative results in a SOS chromotest
with genetically engineered E. coli. The maximum induction factor (Imax) with p-mentha-1,8-dien-7-al
was calculated to be 1.0. Positive results are considered to be signiﬁcant if the Imax is at least 1.5. The
SOS chromotest is also not a mutation test. It measures induction of the SOS repair system, and this
is interpreted as indicating DNA damage. The results cannot therefore be considered to carry as much
weight as results from recommended standard assays.
Standard chromosomal aberration (CA) assays for p-mentha-1,8-dien-7-al have yielded positive
results. In a CA study by Ishidate et al. (1984), Chinese hamster lung (CHL) ﬁbroblasts were only
treated in the absence of S9-mix for 24 or 48 h with a batch of 93.1% purity. There were no
treatments in the presence of S9-mix. Concentrations for the main CA test were selected from a
preliminary experiment in which cell density (a crude and subjective measure) on the culture dishes
was assessed, but there was no concurrent measure of cytotoxicity in the CA test. Only single cultures
of CHL cells were treated with each of three concentrations, and therefore only 100 cells/concentration
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were scored for CA. CA (including gaps) frequencies of 4.9% or less were considered negative,
5.0–9.9% were equivocal, and 10% or higher were considered positive. p-Mentha-1,8-dien-7-al gave
a strong positive response (39% cells with CA, and also an increase in polyploid cells to 31%) at
50 lg/mL. In particular, structural CAs were detected at 40 lg/mL at 24 h (20.0%) and at 48 h
(28.0%); the strongest effect was observed at 50 lg/mL at 24 h. An increase in polyploidy cells was
also detected at 40 lg/mL (15%) and 50 lg/mL (31%) after 48 h. As there was no concurrent
measure of cytotoxicity, and the results at the other concentrations tested were not given, these
results should be considered with caution; however, they cannot be completely dismissed. In the CA
study of Tayama et al. (1990) in CHO-K1 cells, a signiﬁcant increase in CA at 150 lg/mL in the
absence of S9-mix was associated with no detectable cell division. This result can probably be
dismissed as likely to be an artefact of high levels of cell killing. However, a signiﬁcant increase in CA
at 300 lg/mL in the presence of S9-mix was associated with 62% proliferating cells, which does not
indicate excessive toxicity. Most of the chromosome aberrations were chromatid exchanges. These
results are clearly in contrast to the negative micronucleus results obtained in human lymphocytes in
the recent GLP study (Lloyd, 2009). The reasons of such discrepancy are unclear.
A sister chromatid exchange (SCE) assay was performed with and without metabolic activation in
CHO-K1 cells at concentrations up to 300 lg p-mentha-1,8-dien-7-al/ml (Tayama et al., 1990).
Cytotoxicity was determined by the percentage of cells that showed differentially stained chromatids,
i.e. had divided. A doubling of SCE/cell would usually be considered biologically relevant, and in the
absence of S9-mix, there was a doubling of SCE/cell at 150 lg/ml, where there was little toxicity,
whereas in the presence of S9-mix, there was a doubling of SCE/cell at all concentrations from 100–
300 lg/mL, where there was low or moderate toxicity. However, SCE assays also only provide limited
information for assessment of genotoxicity. The mechanism of induction of SCE, and its relevance for
mutation and cancer is not understood.
Studies for induction of ouabain resistant mutants conducted in human fetus cells (Rsa) at
concentrations of 0, 0.010, 0.015, 0.020 or 0.025 lg/mL gave negative results for p-mentha-1,8-dien-
7-al at the lowest concentration, positive results (8–16-fold increases) for concentrations ranging from
0.015 to 0.02 lg/mL (where toxicity was slight to moderate), and showed p-mentha-1,8-dien-7-al to
be cytotoxic at the highest concentration (Suzuki et al., 1990). In another mutagenicity study with Rsa
cells (Suzuki and Suzuki, 1994), induction of ouabain resistance was reported at concentrations above
10 ng p-mentha-1,8-dien-7-al/ml with apparent cytotoxicity at 20 ng/mL or higher. Also, in this study,
mutagenicity was detected (K-ras codons) at concentrations of 2–200 ng/mL. Human fetal (Rsa) cells
are not routinely used for genotoxicity testing, so evaluation of the quality of the data is difﬁcult. The
concentrations used in these tests are much lower than in other mammalian cell tests, and possible
reasons for the discrepancy are not clear. Sasaki et al. (1990) tested p-mentha-1,8-dien-7-al for
induction of ouabain-resistant mutants in CHO-K1 cells. The mutant frequency at the only
concentration of p-mentha-1,8-dien-7-al tested (10 lg/mL, which reduced survival to 83.5% of
controls) appears to be low (0.7 mutants per 106 cells, compared to zero in controls) and the result
would probably be considered negative. The study of ouabain resistance in all of these studies makes
interpretation difﬁcult. Ouabain resistance is generally considered not to be a sensitive mutagenic
target (spontaneous frequencies very low; frame-shift mutations not detected), and it is difﬁcult to
conclude negative results when there is a zero incidence of effects in controls. The biological
signiﬁcance of large increase in ouabain resistant mutants at very low concentrations is equally difﬁcult
to interpret. This endpoint is no longer used in regulatory testing.
The in vitro studies described above are listed in Appendix B, Table B.1.
2.4.2.2. In vivo data
In vivo mutagenicity/genotoxicity testing has been performed on the FGE.19 subgroup 2.2
representative substance p-mentha-1,8-dien-7-al (Appendix B, Table B.2). Eight-week-old male ddY
mice were administered a single intraperitoneal injection of p-mentha-1,8-dien-7-al [FL-no: 05.117] at
doses of 75, 150, 300 or 600 mg/kg body weight (bw) for a mouse micronucleus assay (six mice/
group). The dosing regimen and the maximum dose were based on a pilot experiment with two mice/
group. In the main experiment, after 24 h, the mice were killed and femoral bone marrow cells were
collected, ﬁxed and stained with Giemsa. One thousand polychromatic erythrocytes (PCE) were scored
per mouse. No indication of micronucleus induction was reported at any dose level (Hayashi et al.,
1988). However, the study does not comply with current guidelines, because, after a single
administration, groups of animals should be sacriﬁced 24 and 48 h later. Also, only 1,000 PCE were
scored per animal, whereas the current recommendation is for 2,000 PCE/animal.
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2.4.3. Discussion
EFFA has submitted three valid, new in vitro studies, one in bacteria (Ames test) and two in
mammalian cells (micronucleus (MN) in human lymphocytes and HPRT in mouse lymphoma cells). The
Ames test resulted positive, in the absence of metabolic activation with strain TA98, able to detect
gene mutations of frameshift type (insertions/deletions). Equivocal results were reported in the HPRT
assay (negative according to the authors) and negative results were reported in the MN test. Equivocal
or negative results in the HPRT assay cannot dismiss the positive ﬁndings in the new Ames test,
positive in the TA98 strain. The different results may be due to a different sensitivity of the two tests
to detect frameshift mutations. In this respect, the Panel noted that the molecular analysis of
mutational spectra at the hprt locus show a prevalence of GC to AT transitions and AT to CG
transversions among spontaneous mutants, with less than 10% of frameshifts (Chen et al., 2002).
Thus, given the prevailing contribution of mutations different from frameshift to the baseline incidence
of hprt mutant colonies, it is expected that a many-fold increase in frameshift mutations is needed to
give raise to an overall increase in mutation frequency which is detectable and signiﬁcant on statistical
grounds. The Ames test is generally considered as the most sensitive in vitro test for the prediction of
genotoxic carcinogens and ‘false positive results’ are rare; in this case, the positivity in the TA98
cannot be considered as a ‘false positive’ without any explanation.
Negativity in mammalian cells ‘per se’ cannot be considered more relevant than positivity in
bacteria, simply on the basis of the complexity of cells. Among the previously supplied data, several
in vitro and one in vivo mutagenicity/genotoxicity published studies are available. For most of them,
performed not in compliance with current guidelines, the quality of data was limited. Negative results
were reported in a study with the Ames test; however, the results were only reported as + or , and
therefore could not be veriﬁed. Both positive and negative results were reported for induction of
ouabain gene mutations in mammalian cells, in limited studies. Ouabain resistance is generally
considered of low sensitivity, compared with other gene mutation assays and is unable to detect
mutations of frameshift type; it is no longer routinely used for regulatory purposes. Strong clastogenic
effects in the absence of S9-mix were reported in Chinese hamster cell lines in two papers.
Notwithstanding some limitations of the study, these positive results cannot be completely dismissed
by the negative results in the new in vitro MN assay. The different types of cells used (Chinese
hamster cell lines and human lymphocytes) and the different concentrations used can only partially
explain the different results, which remain unclear. Negative results were reported in a mouse MN
assay, in a study of limited validity for inadequate experimental design and insufﬁcient presentation of
data. Other published results, both positive and negative for DNA-damage/repair (rec-assay) in
bacteria, negative for SOS and positive for SCE in mammalian cells, are not considered as relevant for
the assessment of the genotoxic potential of p-mentha-1,8-dien-7-al.
2.4.4. Conclusion
Overall, the presently available data raise some concern for the genotoxic potential of p-mentha-
1,8-dien-7-al [FL-no: 05.117]. In order to clarify the genotoxic potential of this substance, the
Panel considered that further in vivo testing should be performed. To address this, an in vivo Comet
assay, considering the ﬁrst site of contact (e.g. stomach or duodenum) and liver, should be carried out
according to the Scientiﬁc Report of EFSA on Minimum Criteria for the acceptance of in vivo alkaline
Comet Assay Reports (EFSA, 2012).
2.5. Additional genotoxicity data evaluated by the Panel in
FGE.208Rev18
In response to the EFSA request, in FGE.208, to provide in vivo genotoxicity data for the
representative substance p-mentha-1,8-dien-7-al [FL-no: 05.117], industry has submitted a combined
in vivo bone marrow micronucleus test and Comet assay with scoring in the liver and duodenum
(Appendix C, Table C.1).
p-Mentha-1,8-dien-7-al [FL-no: 05.117] (purity 94.2%) was tested for its ability to induce
micronuclei in the PCE of the bone marrow of treated rats and the potential to induce DNA damage in
the liver and duodenum of the same animals in a combined in vivo micronucleus and Comet assay
(Beevers, 2014a,b).
8 The data presented in Section 2.5 are cited from the Scientiﬁc Opinion FGE.208Rev1.
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Based on results from a range ﬁnding study, where no substantial inter-sex differences in toxicity
were observed in rats, a dose of 700 mg/kg bw per day was considered as the maximum tolerated
dose (MTD). Groups of six male out-bred Han Wistar rats were administered doses of 175, 350 and
700 mg/kg bw of p-mentha-1,8-dien-7-al by oral gavage at time 0, 24 and 45 h. All doses were
administered at a dose volume of 10 mL/kg. Rats were sacriﬁced and sampled at 48 h post the initial
dose. Negative (corn oil) and positive control groups (ethyl methanesulfonate (EMS) 150 mg/kg, dosed
at 0, 24 and 45 h) were included in the main study.
Clinical signs of toxicity were limited to animals dosed at 700 mg/kg bw per day, where reduced
levels of activity were observed in ﬁve out of six animals dosed with p-mentha-1,8-dien-7-al. In
addition, one animal displayed symptoms of ataxia and one animal had piloerection. Dose-related
decreases in body weight gain, or weight loss were observed at all dose levels. No clinical signs of
toxicity were seen in the vehicle or the positive control (EMS).
During clinical chemistry assessment of blood samples, it was noted that a high number of samples
were lipaemic. This was attributed to the corn oil used as a vehicle control and for test article
formulation, which was administered just 3 h prior to blood sampling. As a consequence, many
samples were deemed unsuitable for the analysis of certain parameters and the data were interpreted
with caution. There was a slight increase in aspartate aminotransferase and alanine aminotransferase
at the 700 mg/kg bw per day dose.
The anatomical pathology examination showed that there were no gross lesions in tissues of
exposed animals related to administration of p-mentha-1,8-dien-7-al; however, histopathology revealed
hepatocyte vacuolation at the dose of 700 mg/kg bw per day.
In line with the requirement of the OECD test guideline 474 (OECD, 1997c), the plasma samples
were collected. However, analysis of these samples was not conducted since in this case, this is not
relevant for the interpretation of the study.
2.5.1. Micronucleus assay
An in vitro micronucleus assay in human peripheral blood lymphocytes (Lloyd, 2009) was evaluated
by the Panel as negative in FGE.208. Although not requested, the applicant has submitted an in vivo
micronucleus assay in bone marrow of rats (Beevers, 2014a). In this in vivo study, the proportion of
immature among total (immature + mature) erythrocytes was determined for each animal by counting
a total of at least 500 cells and then at least 2,000 immature erythrocytes per animal were scored for
the incidence of micronucleated polychromatic erythrocytes (MNPCE). Rats treated with p-mentha-1,8-
dien-7-al exhibited %PCE values that were similar to the concurrent vehicle control group and which
were within the laboratory0s historical negative control data, thus indicating that the test substance
was not toxic to the bone marrow. Rats treated with p-mentha-1,8-dien-7-al exhibited group mean
frequencies of MNPCE that were similar to and not statistically different (chi-square calculation) from
those observed in concurrent vehicle controls for all dose groups and were also within the historical
control values (Beevers, 2014a).
The Panel concluded that in this study p-mentha-1,8-dien-7-al did not induce micronucleated
erythrocytes in rat bone marrow cells following administration by oral gavage at the test conditions
performed. There was no indication that the test substance reached the target organ. Negative results
were observed in an in vitro micronucleus test (Lloyd, 2009). Therefore, there is no need to validate
the negative result of the in vivo micronucleus assay and to investigate the target tissue exposure.
2.5.2. Comet assay
2.5.2.1. Duodenum analysis
There was no dose-related increase in % clouds in duodenum cells following treatment with
p-mentha-1,8-dien-7-al, thus demonstrating that treatment did not cause excessive DNA damage that
could have interfered with Comet analysis. Measurements of tail intensity (% DNA in tail) and tail
moment were obtained from 150 cells/animal.
Group mean tail intensity and tail moment values for all groups of animals treated with p-mentha-
1,8-dien-7-al at 175, 350 and 700 mg/kg bw per day were comparable with the group mean vehicle
control data. There were no marked differences in tail intensity between the treated and control
groups. All individual animal data at all dose levels were consistent with the vehicle control animal data
(Beevers, 2014b).
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The Panel concluded that p-mentha-1,8-dien-7-al did not induce DNA damage in the duodenum of
treated male rats under the test conditions performed.
2.5.2.2. Liver analysis
There was no dose-related increase in % clouds or % cells with halos in liver cells following
treatment with p-mentha-1,8-dien-7-al, thus demonstrating that treatment did not cause excessive
DNA damage that could have interfered with Comet analysis. However, clinical chemistry of blood
showed a slight increase in aspartate aminotransferase and alanine aminotransferase at the highest
dose tested, indicating that the liver was exposed to the test substance.
Measurements of tail intensity (% DNA in tail) and tail moment were obtained from 150 cells/
animal.
Group mean % tail intensity and tail moment values for animals treated with p-mentha-1,8-dien-7-
al at the low and medium dose (175 and 350 mg/kg bw per day, respectively) were comparable with
the group mean vehicle control data and there were no statistically signiﬁcant differences in % tail
intensity between treated and control groups. In groups treated with the low and medium dose, all
individual animal data were consistent with the values of the vehicle control animals and fell within the
laboratory’s historical control data.
At the highest dose (animals exposed to 700 mg/kg bw per day), a 3.4-fold and statistically
signiﬁcant increase in tail intensity was observed. A statistically signiﬁcant linear trend was also
apparent. Five out of the six animals treated with the highest dose had tail intensities that exceeded
the values observed in the concurrent vehicle control animals, however, the tail intensity values for all
animals fell within the laboratory’s historical vehicle control values (Beevers, 2014a).
The Panel noted that the range for both the negative and positive historical control values were
extremely wide for this test laboratory. In addition, there was an overlap of the negative (95% range:
0.02–11.39) and positive (95% range: 7.15–65.07) control values.
The Comet arm of this study indicates that p-mentha-1,8-dien-7-al induces DNA damage in liver.
2.5.3. Conclusion
The data submitted by the applicant were considered to be in accordance with the data requested
by the Panel in FGE.208. Industry submitted a Comet assay on the liver and duodenum, and in
addition (although not requested), a micronucleus assay in the bone marrow of the same animals
(combined bone marrow micronucleus test and Comet assay).
p-Mentha-1,8-dien-7-al [FL-no: 05.117] did not induce any increase in micronucleated PCE of the
bone marrow of male rats following oral gavage administration up to 700 mg/kg bw per day (an
estimate of the MTD for this study). There was no indication in the study that the test substance
reached the bone marrow. Negative results were observed in an in vitro micronucleus assay on human
peripheral blood lymphocytes performed according to OECD test guideline 487. Therefore, there is no
need to validate the negative result of the in vivo micronucleus assay and to investigate the target
tissue exposure.
p-Mentha-1,8-dien-7-al did not induce DNA damage in the duodenum of the same animals as
analysed by the Comet assay.
In the same animals, a statistically signiﬁcant increase in DNA strand breaks was observed in the
liver at the highest tested dose (700 mg/kg bw per day).The observed values for tail intensity
(2.20  0.6) and tail moment (0.24  0.07) fell within the test laboratories historical vehicle control
range values for tail intensity (0.02–11.39) and tail moment (0.01–1.45); however, ﬁve of the six high-
dose animals had tail intensities that exceeded the values of the concurrent vehicle control animals.
The Panel noted that the results observed at the highest dose were more than threefold higher
than the concurrent negative control value and statistically signiﬁcant different from the negative
control value. In addition, a statistically signiﬁcant positive linear trend was observed. The
Panel considered that, since there was a wide range of historical control data with an overlap of the
positive and negative historical control values, the historical control data could not be used as a
criterion to interpret the data.
Overall, the Panel concluded that p-mentha-1,8-dien-7-al [FL-no: 05.117] is genotoxic in vivo and
that, accordingly, there is a safety concern for the use of p-mentha-1,8-dien-7-al [FL-no: 05.117] as a
ﬂavouring substance.
Since p-mentha-1,8-dien-7-al [FL-no: 05.117] is representative for the nine remaining substances of
this subgroup 2.2 (p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], myrtenal [FL-no:
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05.106], 2,6,6-trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121], myrtenyl formate [FL-no:
09.272], p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278], myrtenyl acetate [FL-no: 09.302], myrtenyl-
2-methylbutyrate [FL-no: 09.899] and myrtenyl-3-methylbutyrate [FL-no: 09.900]), there is a potential
safety concern for these substances.
3. Assessment
3.1. Additional genotoxicity data evaluated by the Panel in FGE.208Rev2
The applicant has submitted in vitro genotoxicity studies for p-mentha-1,8-dien-7-ol [FL-no: 02.060],
myrtenol [FL-no: 02.091], myrtenal [FL-no: 05.106], myrtenyl acetate [FL-no: 09.302] and
p-mentha-1,8-dien-7-yl acetate [FL-no: 09.278] listed in Table 3. These studies are evaluated in the
present revision of FGE.208 (FGE.208Rev2). A summary of results is reported in Appendix D, Table D.1.
3.1.1. p-Mentha-1,8-dien-7-ol [FL-no: 02.060]
3.1.1.1. Reverse bacterial mutation assay
In order to investigate the potential of p-mentha-1,8-dien-7-ol [FL-no: 02.060] (purity ≥ 90.3%)
and/or its metabolites to induce gene mutations in bacteria, an Ames test was performed according to
OECD Test Guideline 471 (OECD, 1997a) and following GLP in four strains of S. Typhimurium (TA98,
TA100, TA1535 and TA1537) and E. coli WP2uvrA, in the presence or absence of metabolic activation
in two separate experiments. The test article was evaluated in the initial mutagenicity assay at
concentrations of 10, 33.3, 100, 333, 1,000 and 3,333 lg/plate with and without S9-mix, applying the
plate incorporation method. Toxicity was observed at 3,333 lg/plate both in the presence and absence
of S9-mix in most of the strains, except TA100 and TA1535, showing slightly reduced background at
≥ 1,000 lg/plate, with and without S9-mix. In the conﬁrmatory assay, p-mentha-1,8-dien-7-ol was
tested at concentrations of 1, 3.33, 10, 33.3, 100, 333, 1,000 and 3,333 lg/plate with and without
S9-mix, applying the pre-incubation method. Toxicity was observed at concentrations ≥ 333 lg/plate
without S9 activation and at concentrations ≥ 1,000 lg/plate in the presence of S9 activation. No
precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
Appropriate positive control chemicals and dimethyl sulfoxide (DMSO, as vehicle control) were
evaluated concurrently and all test and control articles were evaluated in triplicate plates. All positive
control chemicals induced signiﬁcant increases in revertant colony numbers, conﬁrming the sensitivity
of the tests and the efﬁcacy of the S9-mix, while negative controls were within the historical control
ranges. No increase in the mean number of revertant colonies was observed at any tested
concentration in any tester strains with or without S9-mix (Wagner, 2016).
The Panel considered the results of this assay as negative.
Table 3: List of in vitro genotoxicity studies evaluated in FGE.208Rev2
Substance name FL-no Study
p-Mentha-1,8-dien-7-ol 02.060 Bacterial reverse mutation assay (Wagner, 2016)
Micronucleus assay in human peripheral blood lymphocytes
(Roy, 2016)
Myrtenol 02.091 Bacterial reverse mutation assay (Bhalli and Phil, 2015a)
Micronucleus assay in human peripheral blood lymphocytes
(Bhalli and Phil, 2015b)
BlueScreenTM HC assay (Birrell, 2013a)
Myrtenal 05.106 Bacterial reverse mutation assay (Mc Garry, 2016a)
Micronucleus assay in human peripheral blood lymphocytes
(Mc Garry, 2016b; Lloyd, 2017)
p-Mentha-1,8-dien-7-yl acetate 09.278 Bacterial reverse mutation assay (Lloyd, 2016a)
Micronucleus assay in human peripheral blood lymphocytes
(Lloyd, 2016b)
Myrtenyl acetate 09.302 Bacterial reverse mutation assay (Mc Garry, 2016c)
Micronucleus assay in human peripheral blood lymphocytes
(Mc Garry, 2016d)
BlueScreenTM HC assay (Birrell, 2013b)
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3.1.1.2. In vitro micronucleus assay
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD, 2014)
and following GLP. Human peripheral blood lymphocytes from healthy donors, stimulated with
phytohaemagglutinin (PHA), were treated with p-mentha-1,8-dien-7-ol [FL-no: 02.060] (purity ≥ 90.3%)
(Roy, 2016) in a dose-range ﬁnding assay performed at concentrations ranging from 1 to 1,520 lg/mL for
4 h with and without S9-mix and 24 h without S9-mix. At the termination of the treatment period,
precipitate and hemolysis were observed at concentrations ≥ 1,000 lg/mL and ≥ 400 lg/mL,
respectively, in all three treatment conditions.
Based on the dose-range ﬁnding results, duplicate cultures of lymphocytes were treated with the
test article 44–48 h after culture initiation at concentrations ranging from 100 to 375 lg/mL for 4 h
with and without S9-mix.
Cytochalasin B (ﬁnal concentration of 6 lg/mL) was added to each culture after the 4-h treatment
period, while in the 24-h treatment cultures were treated with the test article in the presence of
cytochalasin B.
Appropriate vehicle (DMSO) and positive controls were used (mitomycin C and vinblastine in the
absence of S9-mix, cyclophosphamide in the presence of S9-mix). All positive control compounds
induced a statistically signiﬁcant increase of MN frequency and the system was considered sensitive
and valid.
Two thousand cells were scored per concentration. Based on the level of cytotoxicity observed,
three concentration levels were selected for MN analysis in each experimental condition: i) 25, 50
and 100 lg/mL, 24 h treatment (16%, 31% and 58% cytotoxicity, respectively); ii) 100, 250 and
325 lg/mL, 4 h treatment without S9-mix (16%, 24% and 58% cytotoxicity, respectively); iii) 100,
225 and 275 lg/mL, 4 h treatment with S9-mix (3%, 18% and 51% cytotoxicity, respectively). No
statistically signiﬁcant increase in the frequency of micronuclei was observed after treatment with the
test article at any concentration analysed (Roy, 2016).
The Panel considered the results of this assay as negative.
3.1.2. Myrtenol [FL-no: 02.091]
3.1.2.1. Reverse bacterial mutation assay
In order to investigate the potential of myrtenol (purity ≥ 97%) and/or its metabolites to induce
gene mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471
(OECD, 1997a) and following GLP in four strains of S. Typhimurium (TA98, TA100, TA1535 and
TA1537) and E. coli WP2uvrA, in the presence or absence of metabolic activation applying the plate
incorporation method. The test article was evaluated in the initial mutagenicity assay at concentrations
of 5, 16, 50, 160, 500, 1,600 and 5,000 lg/plate with and without S9-mix. A conﬁrmatory assay was
subsequently performed at concentrations of 16, 50, 160, 500, 1,600 and 5,000 lg/plate with and
without S9-mix. Appropriate positive control chemicals and DMSO (as vehicle control) were evaluated
concurrently, and all test and control articles were evaluated in triplicate plates. All positive control
chemicals induced signiﬁcant increases in revertant colony numbers, conﬁrming the sensitivity of the
tests and the efﬁcacy of the S9-mix, while negative controls were within the historical control ranges.
No precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
Toxicity, as evident by the absence or reduction in the mean number of revertant colonies and the
absence or reduction in the background bacterial lawn, was observed in both experiments at
5,000 lg/plate in all tester strains with and without S9-mix, except WP2uvrA, where toxicity was
observed at concentrations ≥ 1,600 lg/plate without S9-mix. No increase in the mean number of
revertant colonies was observed at any tested concentration in any tester strains with or without
S9-mix (Bhalli and Phil, 2015a).
The Panel considered the results of this assay as negative.
3.1.2.2. In vitro micronucleus assay
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD,
2010) and following GLP. Human peripheral blood lymphocytes from healthy donors, stimulated with
PHA, were treated with myrtenol (purity ≥ 97%) in a dose-range ﬁnding assay performed in single
cultures at concentrations ranging from 28.2 to 1,000 lg/mL for 3 h with and without S9-mix and 24 h
without S9-mix. No precipitate was observed at the end of treatment and/or harvest at any tested
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concentration in any treatment condition. In the 3-h treatment, haemolysis was observed at
1,000 lg/mL at the end of treatment.
Based on the dose-range ﬁnding results, duplicate cultures of lymphocytes were treated with the
test article 48 h after culture initiation at concentrations ranging from 15.3 to 80.0 lg/mL in the 24-h
treatment. The test article was also evaluated in the 3-h treatment at 224–500 lg/mL with and
without S9-mix.
Cytochalasin B (ﬁnal concentration of 6 lg/mL) was added to each culture after the 3-h treatment
period, while in the 24-h treatment cultures were treated with the test article in the presence of
cytochalasin B. Appropriate vehicle (DMSO) and positive controls were used (mitomycin C in the
absence of S9-mix, cyclophosphamide in the presence of S9-mix). All positive control compounds
induced a statistically signiﬁcant increase of MN frequency and the system was considered sensitive
and valid.
Two thousand cells were scored per concentration. Based on the level of cytotoxicity observed, at
least three concentration levels were selected for MN analysis in each experimental condition: i) 30.6,
47.2 and 52.5 lg/mL with the 24-h treatment (26%, 41% and 54% cytotoxicity, respectively); ii) 407,
451 and 475 lg/mL with the 3-h treatment with S9-mix (15%, 34% and 46% cytotoxicity,
respectively); iii) 368, 387, 451 and 475 lg/mL with the 3-h treatment without S9-mix (19%, 35%,
43% and 64% cytotoxicity, respectively). No statistically signiﬁcant increase in the frequency of
micronuclei was observed after treatment with the test article at any concentration analysed compared
to the respective concurrent vehicle controls (Bhalli and Phil, 2015b).
The Panel considered the results of this assay as negative.
3.1.2.3. BlueScreenTM HC assay
Myrtenol [FL-no: 02.091] was tested in a BlueScreenTM HC assay for cytotoxicity and genotoxicity
using a genetically modiﬁed strain of cultured human lymphoblastoid TK6 cells, both in the presence
and absence of metabolic activation. The study authors concluded that myrtenol did not induce
genotoxicity at the concentrations tested (Birrell, 2013a).
3.1.3. Myrtenal [FL-no: 05.106]
3.1.3.1. Reverse bacterial mutation assay
In order to investigate the potential of myrtenal (purity 97.7%) and/or its metabolites to induce gene
mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471 (OECD, 1997a)
and following GLP in ﬁve strains of S. Typhimurium (TA98, TA100, TA1535, TA1537 and TA102), in the
presence or absence of metabolic activation, in two separate experiments. In the ﬁrst experiment,
myrtenal was tested at concentrations of 5, 16, 50, 160, 500, 1,600 and 5,000 lg/plate with and without
S9-mix, applying the plate incorporation assay. In the second experiment, myrtenal was tested at
concentrations of 80, 160, 300, 625, 1,250, 2,500 and 5,000 lg/plate with and without S9-mix, applying
the pre-incubation method. Appropriate positive control chemicals and DMSO (as vehicle control) were
evaluated concurrently. All test and positive control articles were evaluated in triplicate plates; the vehicle
control was evaluated in quintuplicate.
All positive control chemicals induced signiﬁcant increases in revertant colony numbers, conﬁrming
the sensitivity of the tests and the efﬁcacy of the S9-mix, while negative controls were within the
historical control ranges.
No precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
In the ﬁrst experiment, toxicity, as evident by the absence or reduction in the mean number of
revertant colonies and the absence or reduction in the background bacterial lawn, was observed at
1,600 and/or 5,000 lg/plate in all tester strains in the absence and in the presence of S9-mix.
In the second experiment, toxicity was observed at concentrations of 1,250 and/or 2,500 lg/plate
and above in all strains in the absence of S9-mix. Toxicity was observed at 300 and/or 625 lg/plate
and above for all strains in the presence of S9-mix.
No increase in the mean number of revertant colonies was observed at any tested concentration in
any tester strains with or without S9-mix (Mc Garry, 2016c).
The Panel considered the results of this assay as negative.
3.1.3.2. In vitro micronucleus assay (Mc Garry, 2016b)
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD,
2014) and following GLP. Human peripheral blood lymphocytes from healthy donors, stimulated with
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PHA, were treated with myrtenal (purity 97.7%). Based on the level of cytotoxicity observed in a
preliminary dose-range ﬁnding assay, at least three concentration levels were selected for MN analysis
in each experimental condition: i) for the 24-h treatment with no recovery period (24 + 0 h), the
concentrations of 15, 25 and 34 lg/mL (0, 25% and 55% cytotoxicity, respectively) were selected; ii)
for the 3-h treatment with 21 h recovery period (3 + 21 h) with S9-mix, the concentrations of 25, 200
and 350 lg/mL (0, 26% and 53% cytotoxicity, respectively) were selected; iii) for the 3-h treatment
with 21 h recovery period (3 + 21 h) without S9-mix, the concentrations of 50, 130 and 180 lg/mL
(8%, 25% and 51% cytotoxicity, respectively) were selected. In the treatment of 3 + 21 h with
S9-mix, precipitate was observed at 350 lg/mL.
Cytochalasin B (ﬁnal concentration of 6 lg/mL) was added to each culture after the 3-h treatment
period, while in the 24-h treatment cultures were treated with the test article in the presence of
cytochalasin B. Appropriate vehicle (DMSO) and positive controls were used (mitomycin C and
noscapine in the absence of S9-mix, cyclophosphamide in the presence of S9-mix). Two thousand cells
were scored per concentration.
In the absence of S9-mix, the positive control compounds induced a statistically signiﬁcant increase
of MN frequency and the authors of the study report considered the system as sensitive and valid.
However, the Panel noted that the positive control cyclophosphamide used for the experiment
performed in the presence of S9-mix resulted in a mean frequency of 1.50% MNBN cells (1.60% on
slide A and 1.40% on slide B). The authors of the study report considered that both replicate cultures
demonstrated MNBN cell frequencies that were statistically signiﬁcantly different from the concurrent
vehicle control and clearly exceeded the normal range of negative control data. The Panel, however,
noted that the effects observed with the two replicate cultures of the positive control did not clearly
exceed the normal range (observed range 0.00–1.40%, 95th percentile range 0.10–0.90%) which
raises some concern about the validity of the study. In addition, the Panel observed that the historical
negative control data given in the study report were from August 2012 to August 2013, while the
experiments were performed from October to December 2015. The Panel considered that historical
control data covering the time preceding the current experiments would be more appropriate and
noted that historical data for positive control substances were not reported.
After short treatment (3 + 21 h) in the presence of S9-mix at 350 lg/mL of myrtenal, an elevated
MNBN cells frequency (4.9%) was observed in one replicate culture. According to the study authors,
bacterial contamination was reported on this slide, which may have affected the frequency of MNBN
cells and, thus, the slide was excluded from the analysis. The Panel, however, noted that a bacterial
contamination in only one slide from the same culture was unlikely. In addition, the MNBN cell
frequency in a vehicle replicate culture fell outside the historical negative control range.
After continuous treatment (24 + 0 h) without metabolic activation at 15 lg/mL of myrtenal, a
statistically signiﬁcant increase in the frequency of micronuclei was observed but not at 25 and 34 lg/mL.
The MNBN cell frequency of one replicate culture (1.8%) was outside the historical negative control range
(95% range from 0.1% to 1.5%). Based on data on cytotoxicity and MNBN cells, the Panel noted that a
cell cycle delay inﬂuencing the appearance of MNBN cells might have occurred.
In any other treatment conditions and concentrations analysed, myrtenal did not induce a
statistically signiﬁcant increase of MNBN cells.
As described above, the Panel noted that the in vitro micronucleus assay presented some
limitations; therefore, it was requested to repeat the study changing experimental conditions and
concentrations tested (in particular for the continuous treatment (24 h) in the absence of metabolic
activation, to treat cells for 24 h with no recovery period (24 + 0 h) and for 24 h with 24 h recovery
period (24 + 24 h); the concentrations analysed should include a lower range with narrower spacing).
Appropriate historical negative and positive control data should also be included in the study report.
Following the request from the Panel, industry submitted new data on historical controls. However,
also considering these data, the outcome of this study is still equivocal. In addition, industry submitted
a new in vitro MN assay (Lloyd, 2017) that is described below.
3.1.3.3. In vitro micronucleus assay (Lloyd, 2017)
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD,
2014) and following GLP. Whole blood cultures from healthy donors were treated with myrtenal (purity
98.1%) 48 h after culture initiation following two experimental conditions: a short treatment with and
without S9-mix (3 + 21 h recovery) and a continuous treatment without S9-mix (24 + 0 h and
24 + 24 h recovery). Cytochalasin B (ﬁnal concentration of 6 lg/mL) was added to each culture after
treatment periods, while in the 24-h treatment without recovery cultures were treated with the test
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article in the presence of cytochalasin B (Lloyd, 2017). Appropriate vehicle (DMSO) and positive
controls were used (mitomycin C, noscapine and vinblastine in the absence of S9-mix, in the short and
continuous treatments (24 + 0 h and 24 + 24 h), respectively; cyclophosphamide in the short
treatment in the presence of S9-mix). All positive control compounds induced a statistically signiﬁcant
increase of MN frequency and the system was considered sensitive and valid. Two thousand cells were
scored per concentration and, at least, three concentration levels were selected for MN analysis in
each experimental condition: i) 100, 160 and 200 lg/ml at 3 + 21 h treatment without S9-mix (10, 34
and 52% cytotoxicity, respectively); ii) 100, 200, 300 and 350 lg/mL at 3 + 21 h treatment with S9-
mix (4%, 17%, 31% and 54% cytotoxicity, respectively;); iii) 10, 20, 30 and 32 lg/mL at 24 + 0 h
treatment without S9-mix (0, 15%, 48% and 60% cytotoxicity, respectively); iv) 30, 45, 65 and
75 lg/ml at 24 + 24 h treatment without S9-mix (9%, 29%, 35% and 50% cytotoxicity, respectively).
Following 3 + 21 h treatment with S9-mix, precipitation was observed at 300 lg/mL and above. No
statistically signiﬁcant increase in the frequency of MNBN cells was observed at any concentration and
treatment condition except at 24 + 0 h treatment, where a statistically signiﬁcant increase in the
frequency of MNBN cells was observed at 10 and 32 lg/mL (p < 0.05), but not at 20 and 30 lg/mL.
The MNBN cell frequency of one replicate culture at 32 lg/mL (1.3%) exceeded the 95% historical
vehicle control range (0.1–1.19%); however, there was 60% cytotoxicity and these increases were
weak (up to 2.1-fold compared to control). In addition, the effects were not concentration related and
at some concentrations the effects observed between the two replicate cultures were not fully
consistent. Since such deviations between replicate cultures have been observed in both studies and
since the effects obtained with single cultures exceeded the historical 95% vehicle control range in
both studies, it is not fully clear if this is due to normal variability. The mean of MNBN cell frequencies
were, however, within the 95% historical vehicle control range at all concentrations analysed.
The second study (Lloyd, 2017) is considered more reliable than the ﬁrst one (Mc Gary, 2016), but
also this one is not fully adequate to rule out the concern for genotoxicity. The Panel considered that
generally only one of the three criteria for a positive result was fulﬁlled. In the experiment in the
absence of S9-mix after short treatment, there was a statistically signiﬁcant trend test, but there were
no statistically signiﬁcant differences between single concentrations tested and the concurrent control,
while in the experiment in the absence of S9-mix after long treatment, there was no statistically
signiﬁcant trend, however, two concentrations were statistically signiﬁcantly different from the
concurrent control.
The Panel considered that the results of the two in vitro studies (Mc Garry 2016b and Lloyd 2017)
are equivocal and require further clariﬁcation.
3.1.4. p-Mentha-1,8-dien-7-yl acetate [FL-no: 09.278]
3.1.4.1. Reverse bacterial mutation assay
In order to investigate the potential of p-mentha-1,8-dien-7-yl acetate (purity 96.5%) and/or its
metabolites to induce gene mutations in bacteria, an Ames test was performed according to OECD
Test Guideline 471 (OECD, 1997a) and following GLP in ﬁve strains of S. Typhimurium (TA98, TA100,
TA1535, TA1537 and TA102), in the presence or absence of metabolic activation, in two separate
experiments. In the ﬁrst experiment, p-mentha-1,8-dien-7-yl acetate was tested at concentrations of 5,
16, 50, 160, 500, 1,600 and 5,000 lg/plate with and without S9-mix, applying the plate incorporation
assay. In the second experiment, p-mentha-1,8-dien-7-yl acetate was tested at concentrations of 1.6,
5, 16, 50, 160, 500 and 1,600 lg/plate with and without S9-mix, applying the pre-incubation method.
Appropriate positive control chemicals and DMSO (as vehicle control) were evaluated concurrently. All
test and positive control articles were evaluated in triplicate plates; the vehicle control was evaluated
in quintuplicate.
All positive control chemicals induced signiﬁcant increases in revertant colony numbers, conﬁrming
the sensitivity of the tests and the efﬁcacy of the S9-mix, while negative controls were within the
historical control ranges.
No precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
In the ﬁrst experiment, toxicity, as evident by the absence or reduction in the mean number of
revertant colonies and absence or reduction in the background bacterial lawn, was observed at
500 lg/plate and above in all tester strains in the absence of S9-mix and for strain TA1537 in the
presence of S9-mix. For all other strains, in the presence of S9-mix, toxicity was observed at
concentrations above 1,600 lg/plate.
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In the second experiment, toxicity was observed at 500 lg/plate and above in all strains in the
absence of S9-mix and in strain TA1535 and TA102 in the presence of S9-mix. Toxicity was observed
at 160 lg/plate and above in strains TA98, TA100 and TA1537 in the presence of S9-mix.
No increase in the mean number of revertant colonies was observed at any tested concentration in
any tester strains with or without S9-mix (Lloyd, 2016a).
The Panel considered the results of this assay as negative.
3.1.4.2. In vitro micronucleus assay
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD,
2014) and following GLP. Human peripheral blood lymphocytes from healthy donors, stimulated with
PHA, were treated with p-mentha-1,8-dien-7-yl acetate (purity 96.5%) in a dose-range ﬁnding assay
performed in single cultures at concentrations ranging from 7.05 to 1943 lg/mL for 3 h with and
without S9-mix and 24 h without S9-mix. At the time of treatment, precipitate was observed at
concentrations ≥ 151.1 lg/mL in all three treatment conditions.
Based on the dose-range ﬁnding results, duplicate cultures of lymphocytes were treated with the
test article 48 h after culture initiation at concentrations ranging from 25 to 250 lg/mL for treatments
at 3 + 21 h without metabolic activation. Concentrations ranging from 50 to 500 lg/mL were tested in
the treatment at 3 + 21 h with metabolic activation. Concentrations ranging from 10 to 150 lg/mL
were tested in the treatment at 24 h without metabolic activation. Cytochalasin B (ﬁnal concentration
of 6 lg/mL) was added to each culture at the time of treatment. Appropriate vehicle (DMSO) and
positive controls were used (mitomycin C and noscapine in the absence of S9-mix, cyclophosphamide
in the presence of S9-mix). All positive control compounds induced a statistically signiﬁcant increase of
MN frequency and the system was considered sensitive and valid. Two thousand cells were scored per
concentration. Based on the level of cytotoxicity observed, at least three concentration levels were
selected for MN analysis in each experimental condition: i) 30, 60 and 80 lg/mL with the 24-h
treatment (12%, 39% and 55% cytotoxicity, respectively); ii) 150, 240 and 280 lg/mL with the 3-h
treatment with S9-mix (11%, 41% and 55% cytotoxicity, respectively); iii) 100, 120 and 130 lg/mL
with the 3-h treatment without S9-mix (9%, 44% and 67% cytotoxicity, respectively). In the treatment
of 3 + 21 h with S9-mix, precipitate was observed at 150 lg/mL and above. In the treatment of
3 + 21 h without S9-mix, precipitate was observed at 120 and 130 lg/mL. p-Mentha-1,8-dien-7-yl
acetate did not induce a statistically signiﬁcant increase of MNBN cells at any concentration analysed
(Lloyd, 2016b).
The Panel considered the results of this assay as negative.
3.1.5. Myrtenyl acetate [FL-no: 09.302]
3.1.5.1. Reverse bacterial mutation assay
In order to investigate the potential of myrtenyl acetate (purity 97.6%) and/or its metabolites to
induce gene mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471
(OECD, 1997a) and GLP in ﬁve strains of S. Typhimurium (TA98, TA100, TA1535, TA1537 and TA102),
in the presence or absence of metabolic activation, in two separate experiments. In the ﬁrst
experiment, myrtenyl acetate was tested at concentrations of 5, 16, 50, 160, 500, 1,600, and
5,000 lg/plate with and without S9-mix, applying the plate incorporation assay. In the second
experiment, myrtenyl acetate was tested at concentrations of 3.28, 8.2, 20.5, 51.2, 128, 320, 800 and
2,000 lg/plate with and without S9-mix, applying the pre-incubation method. Appropriate positive
control chemicals and DMSO (as vehicle control) were evaluated concurrently. All test and positive
control articles were evaluated in triplicate plates; the vehicle control was evaluated in quintuplicate.
All positive control chemicals induced signiﬁcant increases in revertant colony numbers, conﬁrming
the sensitivity of the tests and the efﬁcacy of the S9-mix, while negative controls were within the
historical control ranges.
No precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
In the ﬁrst experiment, toxicity, as evident by the absence or reduction in the mean number of
revertant colonies and the absence or reduction in the background bacterial lawn, was observed in
both experiments at 500 lg/plate and above in all tester strains in the absence of S9-mix and strain
TA1535 in the presence of S9-mix. For the other four strains, in the presence of metabolic activation,
toxicity was observed at 1,600 lg/plate and above.
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In the second experiment, toxicity was observed at 320 lg/plate and above in strains TA98, TA100,
TA1535 and TA1537 in the presence and absence of S9-mix. In strain TA102, toxicity was observed at
2,000 lg/plate in the presence and absence of S9-mix.
No increase in the mean number of revertant colonies was observed at any tested concentration in
any tester strains with or without S9-mix (Mc Garry, 2016a).
The Panel considered the results of this assay as negative.
3.1.5.2. In vitro micronucleus assay
The in vitro micronucleus assay was carried out according to OECD Test Guideline 487 (OECD,
2014) and following GLP. Human peripheral blood lymphocytes from healthy donors, stimulated with
PHA, were treated with myrtenyl acetate (purity 97.6%) in a dose-range ﬁnding assay performed in
single cultures at concentrations ranging from 7.05 to 1,943 lg/mL for 3 h with and without S9-mix
and 24 h without S9-mix. At the time of treatment, precipitate was observed at concentrations
≥ 250 lg/mL.
Based on the dose-range ﬁnding results, duplicate cultures of lymphocytes were treated with the
test article 48 h after culture initiation at concentrations ranging from 5 to 200 lg/mL for treatments
without metabolic activation. Concentrations ranging from 25 to 500 lg/mL were tested in the
treatment at 3 + 21 h with metabolic activation. Cytochalasin B (ﬁnal concentration of 6 lg/mL) was
added to each culture after the 3-h treatment period, while in the 24-h treatment cultures were
treated with the test article in the presence of cytochalasin B. Appropriate vehicle (DMSO) and positive
controls were used (mitomycin C and noscapine in the absence of S9-mix, and cyclophosphamide in
the presence of S9-mix). All positive control compounds induced a statistically signiﬁcant increase of
MN frequency and the system was considered sensitive and valid. Two thousand cells were scored per
concentration. Based on the level of cytotoxicity observed, at least three concentration levels were
selected for MN analysis in each experimental condition: i) 10, 20 and 40 lg/mL with the 24-h
treatment (2%, 21% and 52% cytotoxicity, respectively); ii) 150, 250 and 325 lg/mL with the 3-h
treatment with S9-mix (7%, 36% and 53% cytotoxicity, respectively); iii) 20, 60, 80 and 90 lg/mL
with the 3-h treatment without S9-mix (0%, 12%, 45% and 48% cytotoxicity, respectively). No
statistically signiﬁcant increase in the frequency of micronuclei was observed after treatment with the
test article at any concentration analysed (Mc Garry, 2016b).
The Panel considered the results of this assay as negative.
3.1.5.3. BlueScreenTM HC assay
Myrtenyl acetate [FL-no: 09.302] was tested in a BlueScreenTM HC assay for cytotoxicity and
genotoxicity using a genetically modiﬁed strain of cultured human lymphoblastoid TK6 cells, both in
the presence and absence of metabolic activation. The study authors concluded that myrtenyl acetate
did not induce genotoxicity at the concentrations tested (Birrell, 2013b).
4. Conclusions
The Panel considered that the newly submitted bacterial reverse mutation assays and the in vitro
micronucleus assays on p-mentha-1,8-dien-7-ol [FL-no: 02.060], myrtenol [FL-no: 02.091], p-mentha-
1,8-dien-7-yl acetate [FL-no: 09.278] and myrtenyl acetate [FL-no: 09.302] were adequately
performed and that the results were negative. Therefore, the concern for genotoxicity could be ruled
out for these four substances. Accordingly, they could be evaluated through the Procedure.
Myrtenal [FL-no: 05.106] did not induce gene mutations in a bacterial reverse mutation assay. The
ﬁrst in vitro micronucleus assay provided was equivocal and had several weaknesses; therefore, a
repetition of the study was requested. The second study is considered more reliable than the ﬁrst one,
but the result is still not fully adequate to rule out the concern for genotoxicity. In this second study, weak
statistically signiﬁcant increases of the micronuclei frequency were observed at the lowest and highest
concentrations (without statistically signiﬁcant trend) in the absence of S9-mix after long treatment,
while after short treatment, there was a statistically signiﬁcant trend (without statistically signiﬁcant
differences between single concentrations tested and the concurrent control). The Panel considered that
the result of this second study was also equivocal and that this was not adequately investigated by the
applicant. Therefore, myrtenal cannot be evaluated through the Procedure, presently.
The Panel also considered two publications on the evaluation of genotoxicity studies on p-mentha-
1,8-dien-7-al [FL-no: 05.117] (Cohen et al., 2016; Hobbs et al., 2016) which were published after the
publication of the scientiﬁc opinion on FGE.208Rev1. The authors presented the same data as those
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reported in FGE.208Rev1, but reached different conclusions compared to the CEF Panel in relation to
the evaluation of the in vivo Comet assay in liver. The Panel considered the reasons provided by the
authors to substantiate their conclusions as not convincing and concluded that these two publications
do not give reason to modify the conclusion drawn on the genotoxicity of p-mentha-1,8-dien-7-al
[FL-no: 05.117] in FGE.208Rev1.
Documentation provided to EFSA
1) Beevers C, 2014a. p-Mentha-1,8-dien-7-al: Combined bone marrow micronucleus test and
Comet assay in the liver of treated rats. Covance Laboratories Ltd. Study no. 8288455. 20
January 2014. Unpublished ﬁnal report submitted by EFFA to EFSA.
2) Beevers C, 2014b. p-Mentha-1,8-dien-7-al: Analysis of Comet slides from Covance Study
8288455. Covance Laboratories Ltd. Study no. 8307194. 05 September 2014. Unpublished
ﬁnal report submitted by EFFA to EFSA.
3) Benigni R and Netzeva T, 2007a. Report on a QSAR model for prediction of genotoxicity of
a,b-unsaturated aldehydes in S. typhimurium TA100 and its application for predictions on a,
b-unsaturated aldehydes in Flavouring Group Evaluation 19 (FGE.19). Unpublished report
submitted by FLAVIS Secretariat to EFSA.
4) Benigni R and Netzeva T, 2007b. Report on a QSAR model for prediction of genotoxicity of
a,b-unsaturated ketones in S. typhimurium TA100 and its application for predictions on a,
b-unsaturated aldehydes in Flavouring Group Evaluation 19 (FGE.19). Unpublished report
submitted by FLAVIS Secretariat to EFSA.
5) Bhalli J and Phil M, 2015a. Myrtenol (CAS # 515-00-4): Bacterial reverse mutation assay:
plate incorporation method with a conﬁrmatory assay. Covance Laboratories Inc. Study no.
8301943. 11 February 2015. Unpublished ﬁnal report submitted by EFFA to EFSA.
6) Bhalli J and Phil M, 2015b. Myrtenol (CAS # 515-00-4): in vitro micronucleus assay in
human peripheral blood lymphocytes. Covance Laboratories Inc. Study no. 8302022. 27
March 2015. Unpublished ﬁnal report submitted by EFFA to EFSA.
7) Birrell L, 2013a. Report on the Testing of 1 Compound (myrtenol) in the BlueScreenTM HC
Assay (/+ S9 Metabolic Activation). Gentronix Limited. Unpublished study report
submitted by EFFA to EFSA.
8) Birrell L, 2013b. Report on the Testing of 1 Compound (myrtenyl acetate) in the
BlueScreenTM HC Assay (/+ S9 Metabolic Activation). Gentronix Limited. Unpublished study
report submitted by EFFA to EFSA.
9) Bowen R, 2011. Reverse mutation in ﬁve histidine-requiring strains of Salmonella
typhimurium. p-Mentha-1,8-dien-7-al. Covance Laboratories Ltd. Study no. 8221207. May
2011. Unpublished report submitted by EFFA to FLAVIS Secretariat.
10) EFFA (European Flavour Association), 2012. Submission by the European Flavour
Association to the European Food Safety Authority. Flavouring Group Evaluation 19
Subgroup 2.2 Flavouring Substance (Flavouring Substances) of the Chemical Group 7
(Annex I of 1565/2000/EC) structurally related to alicyclic primary alcohols, aldehydes, acids
and related esters used as ﬂavouring substances. Alicyclic a,b-unsaturated aldehydes with
the a,b-conjugation in the ring or in the side chain. July 2012. FLAVIS/8.161.
11) EFFA (European Flavour Association), 2016. EFFA Letters to Commission for clariﬁcation of
use levels and updated tonnage data for ﬁve substances in FGE.208Rev2.
12) Gry J, Beltoft V, Benigni R, Binderup M-L, Carere A, Engel K-H, G€urtler R, Jensen GE,
Hulzebos E, Larsen JC, Mennes W, Netzeva T, Niemel€a J, Nikolov N, Nørby KK and Wedebye
EB, 2007. Description and validation of QSAR genotoxicity models for use in evaluation of
ﬂavouring substances in Flavouring Group Evaluation 19 (FGE.19) on 360 a,b-unsaturated
aldehydes and ketones and precursors for these. Unpublished report submitted by FLAVIS
Secretariat to EFSA.
13) Lloyd M, 2009. Induction of micronuclei in cultured human peripheral blood lymphocytes. p
Mentha-1,8-dien-7-al. Covance Laboratories Ltd. Study no. 8200450. July 17, 2009.
Unpublished report submitted by EFFA to FLAVIS Secretariat.
14) Lloyd M, 2012. Mutation at the hprt locus of mouse lymphoma L5178Y cells (MLA) using the
microtitre(R) ﬂuctuation technique. p-Mentha-1,8-dien-7-al. Covance Laboratories Ltd. Study
no. 8250474. June, 2012. Audited draft report. Unpublished report submitted by EFFA to
FLAVIS Secretariat.
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15) Lloyd M, 2016a. p-Mentha-1,8-dien-7-yl acetate: bacterial reverse mutation assay. Covance
Laboratories Ltd. Study no. 8332790. February 2016. Unpublished study report submitted
by EFFA to EFSA.
16) Lloyd M, 2016b. p-Mentha-1,8-dien-7-yl acetate: in vitro human lymphocyte micronucleus
assay. Covance Laboratories Ltd. Study no. 8332794. March 2016. Unpublished study report
submitted by EFFA to EFSA.
17) Lloyd M, 2017. Myrtenal: in vitro human lymphocyte micronucleus assay. Covance
Laboratories Ltd. Study no. 8351223. January 2017. Unpublished study report submitted by
EFFA to EFSA.
18) Mc Garry S, 2016a. Myrtenal: bacterial reverse mutation assay. Covance Laboratories Ltd.
Study no. 8332788. February 2016. Unpublished study report submitted by EFFA to EFSA.
19) Mc Garry S, 2016b. Myrtenal: in vitro human lymphocyte micronucleus assay. Covance
Laboratories Ltd. Study no. 8332792. February 2016. Unpublished study report submitted
by EFFA to EFSA.
20) Mc Garry S, 2016c. Myrtenyl acetate: bacterial reverse mutation assay. Covance
Laboratories Ltd. Study no. 8332789. January 2016. Unpublished study report submitted by
EFFA to EFSA.
21) Mc Garry S, 2016d. Myrtenyl acetate: in vitro human lymphocyte micronucleus assay.
Covance Laboratories Ltd. Study no. 8332793. February 2016. Unpublished study report
submitted by EFFA to EFSA.
22) Nikolov N, Jensen GE, Wedebye EB and Niemel€a J, 2007. Report on QSAR predictions of
222 a,b-unsaturated aldehydes and ketones from Flavouring Group Evaluation 19 (FGE.19)
on 360 a,b-unsaturated aldehydes and ketones and precursors for these. Unpublished
report submitted by FLAVIS Secretariat to EFSA.
23) Roy S, 2016. In Vitro Mammalian Cell Micronucleus Assay in Human Peripheral Blood
Lymphocytes (HPBL) with para-mentha-1,8-dien-7-ol, aka p-mentha-1,8-dien-7-ol (CAS
Number: 536-59-4). BioReliance Corporation. Study no. AE43RY.348.BTL. Unpublished study
report submitted by EFFA to EFSA.
24) Wagner VO, 2016. Bacterial Reverse Mutation with an Independent Repeat Assay with para-
mentha-1,8-dien-7-ol, aka p-mentha-1,8-dien-7-ol (CAS Number: 536-59-4). BioReliance
Corporation. Study no. AE43RY.502002.BTL. Unpublished study report submitted by EFFA to
EFSA.
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Abbreviations
bw body weight
CA chromosomal aberration
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHL Chinese hamster lung (cells)
CoE Council of Europe
DMSO dimethyl sulfoxide
EFFA European Flavour and Fragrance Association
EMS ethyl methanesulfonate
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP Good Laboratory Practice
HPRT hypoxanthine-guanine phosphoribosyl transferase
ID Identity
Imax maximum induction factor
IR infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MN micronucleus
MNBN micronucleated binucleated (cells)
MNPCE micronucleated polychromatic erythrocytes
MS mass spectrometry
MSDI maximised survey-derived daily intake
mTAMDI modiﬁed theoretical added maximum daily intake
MTD maximum tolerated dose
NMR nuclear magnetic resonance
No Number
OECD Organisation for Economic Co-operation and Development
PCE polychromatic erythrocytes
PHA phytohaemagglutinin
(Q)SAR (quantitative) structure–activity relationship
RI replication index
RS relative survival
SCE sister chromatid exchange
WHO World Health Organization
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Appendix E – Exposure
E.1. Presence of myrtenal in food and in other sources
Myrtenal [FL-no: 05.106] is an aromatic constituent of several plant species. Quantitative data are
available for 21 natural sources (including three natural sources, in which myrtenal was found only at
trace level). For further 11 natural sources, only qualitative data are available (Table E.1).
It should be mentioned that not all of the sources reported in Table E.1 are used as foodstuffs or
are added to products sold in the EU market (GNPD, 2017) for ﬂavouring purposes: turpentine oil
(Pistacia terebinthus) is used as a solvent, cleaning and sanitary product; Pistacia atlantica is used in
traditional medicine in Iran, it can also be used in local (Iranian) foods, such as curd, instead of
walnuts (Bahmani et al., 2015).
According to the Global New Products Database (GNPD) (2017),9 some plant sources, i.e. Calabash
nutmeg (Monodora myristica Dunal) and Xylopia species reported in Table E.1, are not reported to be
used in food products placed on the market in the EU.
Table E.1: Occurrence of myrtenal [FL-no: 05.106] in natural sources as reported by (Triskelion,
2017)
Natural source Quantity (mg/kg)
Calabash nutmeg (Monodora myristica Dunal) 600
Camomile < 500–4,600
Citrus fruits(a) < 5–340
Eucalyptus oil (Eucalyptus globulus Labill) 700
Ginger (Zingiber species) 600
Lamb’s lettuce (Valerianella locusta) 0.2–0.5
Laurel (Laurus nobilis L.) 1,700
Licorice (Glycyrrhiza species) 0.5
Mastic (Pistacia lentiscus) 1,300–7,200
Melon 0.04
Mentha oils 2
Myrtle (Myrtus communis L.) 2,200
Parsley (Petroselinum species) 10
Pistachio oil (Pistacia vera) 2,200
Pistacia atlantica 9,000–12,000
Thyme (Thymus species) < 1,000
Turpentine oil (Pistacia terebinthus) 11,000–41,000
Xylopia species 15,000
Calamus (sweet ﬂag) (Acorus calamus L.) Qualitative
Cherimoya (Annona cherimolia Mill.) Qualitative
Cumin seed (Cuminum cyminum L.) Trace (ppm)
Custard apple, atemoya (Annona atemoya) Qualitative
Juniperus communis Qualitative
Lemon balm (Melissa ofﬁcinalis L.) Qualitative
Mace (Myristica fragrans Houttuyn) Trace (ppm)
Mangifera species Qualitative
Nutmeg (Myristica fragrans Houttuyn) Trace (ppm)
Pepper (Piper nigrum L.) Qualitative
Raspberry, blackberry and boysenberry Qualitative
Walnut (Juglans species) Qualitative
(a): Quantitative data on citrus fruits are reported mainly from peel.
9 The Global New Products Database monitors product innovation and retail success in consumer packaged goods markets,
worldwide.
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Myrtle (Myrtle communis L.) berries and leaves are used to make alcoholic-beverages in Italy,
especially in Sardinia, where the smoke of myrtle is also used for ﬂavouring purposes in traditional
cooking. Moreover, myrtle leaves and berries can be used by the food industry for ﬂavouring purposes
and for the production of sweet liquors (Aleksic and Knezevic, 2014). In the EU, myrtle is used not
only in the production of alcoholic beverages, but also in a few other products, e.g. in soothing gum,
tea and jelly in France; in a carbonated soft drink, pear preserve and a juice drink in Italy (GNPD,
2017).
E.1.1. Intended use and use levels of myrtenal as provided by the
Flavour Industry
Use levels in the different food categories reported in Annex I of Reg. (EC) 1565/200010 have been
submitted by the ﬂavour industry and are reported in Table E.2 (EFFA, 2016).
10 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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E.2. Intake data from intended use8
Annual production volumes of the ﬂavouring substances as surveyed by industry are used to
calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) assuming that the production ﬁgure only
represents 60% of the use in food, due to underreporting and that 10% of the total EU population are
consumers (SCF, 1999).
Use levels for myrtenal provided by industry (EFFA, 2016) listed in Table E.2, have been used to
calculate the ‘modiﬁed Theoretical Added Maximum Daily Intake’ (mTAMDI).11
The MSDI and mTAMDI exposure estimates are given in Table E.3.
Table E.3: Exposure to the ﬂavouring substance
FL-no Name
EU MSDI
lg/capita per day
mTAMDI
lg/person per day
05.106 Myrtenal 2.21 2,100
FL-no: FLAVIS number; MSDI: maximised survey-derived daily intake; mTAMDI: modiﬁed Theoretical Added Maximum Daily
Intake.
11 mTAMDI estimation is based in an approach used by the SCF up to 1995 (SCF, 1995) and is calculated on the basis of
standard portions and normal use levels for ﬂavoured beverages and foods in general, with exceptional levels for particular
foods.
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Appendix F – Publications on the evaluation of genotoxicity studies on
p-Mentha-1,8-dien-7-al [FL-no: 05.117]
p-Mentha-1,8-dien-7-al [FL-no: 05.117] was evaluated by the Panel as genotoxic in vivo and,
accordingly, there is a safety concern for the use of p-mentha-1,8-dien-7-al [FL-no: 05.117] as a
ﬂavouring substance (FGE.208Rev1). After the publication of this opinion (EFSA CEF Panel, 2015), two
articles on the genotoxicity of p-mentha-1,8-dien-7-al [FL-no: 05.117] were published (Cohen et al.,
2016; Hobbs et al., 2016), that industry sent to EFSA. The authors presented the same data reported
in EFSA opinion FGE.208Rev1 (EFSA CEF Panel, 2015), but reached different conclusions compared to
the CEF Panel in relation to the evaluation of the in vivo Comet assay in liver. Topics in disagreement
are summarised below.
1) Relevance of in vivo study in liver as follow-up of in vitro genotoxicity tests on
p-mentha-1,8-dien-7-al [FL-no: 05.117]
Hobbs et al. (2016) considered that ‘if the positive test in the liver, the major site of metabolism
in vivo, is assumed to reﬂect a biologically relevant result, then it is surprising that in vitro
mutagenicity and chromosome damage tests performed in the presence of metabolic activation did not
provide any indication of genotoxic effects’ (Hobbs et al., 2016).
The Panel noted that there was some evidence of positive results in vitro also in the presence of
S9-mix (Tayama et al., 1990). While Tayama et al. (1990) observed a positive result in a chromosomal
aberration assay at 300 lg/mL (in the absence of excessive toxicity), Lloyd (2009) observed a negative
result with p-mentha-1,8-dien-7-al in an in vitro micronucleus assay up to 140 lg/mL (accompanied by
45% cytotoxicity which is less than the 50–60% cytotoxicity as recommended by the OECD TG 487).
The inconsistent results obtained by Tayama et al. (1990) and Lloyd (2009) might therefore be due to
the different maximum concentrations tested.
2) Liver toxicity
In the analysis of the Comet assay in liver, the CEF Panel noted:
‘at the highest dose (animals exposed to 700 mg/kg bw per day) a 3.4-fold and statistically
signiﬁcant increase in tail intensity was observed. A statistical signiﬁcant linear trend was also
apparent. Five out of the six animals treated with the highest dose had tail intensities that exceeded
the values observed in the concurrent vehicle control animals’.
The two articles indicate:
‘While this statement is correct, it should be pointed out that only 2 of the 6 animals in this dose
group, are driving the statistically signiﬁcant increase in group mean tail intensity, compared to the
concurrent vehicle control animals. More importantly, these two animals were also among the three
most affected by liver toxicity (animals 27 and 23), indicating a direct association between liver
toxicity and increased DNA tail intensities’. (Cohen et al., 2016).
Referring to ‘A statistical signiﬁcant linear trend was also apparent’, Cohen et al. (2016) indicate:
‘While this statement is accurate, this is also consistent with the reported dose-dependent toxicity’
(Cohen et al., 2016).
‘The lack of dose-related increases in % clouds or % cells with halos in liver cells indicates that
treatment did not cause excessive DNA damage that could have created artefacts and interfered
with comet analysis. However, other endpoints reveal evidence of dose-dependent general liver
toxicity in the test substance-exposed animals, and this effect was particularly pronounced at the
highest dose employed (700 mg/kg bw per day), including a loss of body weight in the high dose
group over the period of exposure to the test substance in 5 of the 6 rats in the group, elevated
aspartate aminotransferase and alanine aminotransferase and altered clinical biochemistry
parameters (cholesterol, potassium, chloride, urea and glucose); three animals (numbered 27, 23
and 22) in the high dose group were particularly affected. Histopathological examination
corroborated the clinical pathology ﬁndings (..) with observations of hepatocyte vacuolation in all 6
animals in the high dose group. Additionally, 5 of the 6 animals in the high dose group showed
overt signs of toxicity reﬂected in their behaviour (reduced activity), particularly animals 27 and 23’
(Cohen et al., 2016).
Flavouring Group Evaluation 208 Revision 2
www.efsa.europa.eu/efsajournal 42 EFSA Journal 2017;15(5):4766
‘In this study, there was no dose-related increase in % hedgehogs or % cells with halos in liver
cells of exposed animals. Five out of the six animals in the 700 mg/kg per day dose group had %
tail intensity values that exceeded those of the concurrent vehicle control animals.’ (..)
‘Measurements were obtained for at least ﬁve animals/group for aspartate aminotransferase (AST)
and alanine aminotransferase (ALT); although mean serum values for these enzymes were not
statistically signiﬁcant, three of the six rats dosed with 700 mg/kg per day perillaldehyde exhibited
high activity of both ALT and AST, indicative of hepatic toxicity’ (..) ‘Hepatocyte cytoplasmic
vacuolation was observed in liver sections from the rats exposed to 700 mg/kg per day
perillaldehyde. The small vacuoles are morphologically consistent with microvesicular fat’ (Hobbs
et al., 2016).
‘The international effort to validate the in vivo comet assay for the detection of genotoxic
carcinogens, coordinated by the Japanese Center for the Validation of Alternative Methods
(JaCVAM), concluded that histopathology remains the “gold standard” for assessing tissue
cytotoxicity, and changes in % tail DNA require careful interpretation when measured in conjunction
with severe histopathological changes (Uno et al., 2015). (..) The perillaldehyde comet ﬁndings
(both the group mean and individual animal data) are well within this upper limit for acceptable
vehicle control values further supporting the conclusion that the small increase in tail intensity
observed in the liver following administration at 700 mg/kg per day was not biologically relevant
and was most likely an artefact of the observed hepatic cytotoxicity’ (Hobbs et al., 2016).
The Panel noted that histopathology has been taken into account in the evaluation of results, as
recommended by OECD TG 489. The authors of the study report indicated ‘In the liver, minimal or
slight hepatocyte vacuolation was present in animals given 700 mg/kg/day’ (Beveers, 2014a). The
Panel noted that vacuolisation is not considered an indication for strong hepatotoxicity. The
Panel considered also clinical chemistry data, which showed a slight increase in aspartate
aminotransferase and alanine aminotransferase at the highest dose that was not statistically
signiﬁcant.
Moreover, the Panel noted the lack of dose-related increase of percent of cells with clouds and
halos (which according to OECD TG489 are key parameters for the interpretation of the comet assay)
conﬁrming the absence of severe liver toxicity. Actually, also the study authors (Beevers, 2014a)
considered that there was no excessive liver damage and liver toxicity at the top dose and that this did
not interfere with the validity of the assay. The Panel noted that if liver toxicity was so severe, as
claimed by the authors of the two articles, the acceptance criteria for the study should not have been
considered as being fulﬁlled. In this respect, the view of the authors of the two articles (Cohen et al.,
2016; Hobbs et al., 2016) is not consistent with the view of the authors of the study report, since the
acceptance criteria have actually been considered as being fulﬁlled by the authors of the study report
and the study was evaluated by them.
3) Historical controls
In the analysis of the Comet assay in liver, the CEF Panel indicated:
‘. . . however, the tail intensity values for all animals fell within the laboratory’s historical control
values. The Panel noted that the range for both the negative and positive historical control values
were extremely wide for this test laboratory. In addition there was an overlap of the negative (95%
range: 0.02–11.39) and positive (95% range: 7.15–65.07) control values’.
The two articles indicate:
‘The observation that tail intensity values for all animals fell within the laboratory’s historical control
values is pertinent and under OECD TG 489 guidelines cannot be dismissed when considering the
outcome of a comet assay. (..) This is indeed the case, but it is important to consider that the tail
intensity for the negative and positive controls of the speciﬁc assay fell comfortably within the range
of the historical control values and near the means of the respective ranges: the positive control tail
intensity is close to the historical positive control mean (35.55  14.86). More importantly, the
mean tail intensity of the high dose group (700 mg/kg bw per day) of 2.20  0.60 is comparable to
the historical negative control mean (2.22  2.58), despite the skew effected by animals 27 and 23’
(Cohen, 2016).
‘However, all six animals fell well within the laboratory’s historical vehicle control 95th percentile
range (0.02–11.39; n = 165) and only two of the six animals had % tail intensity values that
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exceeded the mean % tail intensity of the historical control data (2.22%). (..) In that regard, it is
useful to consider the perillaldehyde positive % tail intensity value in the context of broadened
historical datasets collated by the testing laboratory, in which the vehicle and positive control
reference ranges are clearly distinct (Supplemental Data Table II) (2016). Comparison of the
positive % tail intensity value (2.20%) to historical data that included the studies performed
immediately prior to the perillaldehyde study (n = 230) or historical data spanning the period
immediately prior and subsequent to the perillaldehyde study (n = 400) conﬁrms that the
perillaldehyde data are close to the means of both vehicle control data sets (2.31% and 1.60%
respectively), supporting the arguments that the positive comet result for perillaldehyde is not
biologically relevant (Hobbs et al., 2016)’.
The Panel noted that on the basis of OECD TG 489, the evaluation should be based on a
comparison between treatment-induced values and the concurrent vehicle control, the consideration of
a potential dose-response relationship and on a comparison of treatment-induced values with
(appropriate) historical negative control data, not primarily on a comparison between vehicle/positive
control experimental data and historical controls. Hobbs et al. (2016) report three different ranges of
historical control, two of the reported ranges are new and not overlapping. However, the range of
historical negative control is still wide and no justiﬁcation on the overlapping range is provided. The
Panel did not have access to the broadened dataset when it evaluated p-mentha-1,8-dien-7-al in
FGE.208Rev1 (EFSA CEF Panel, 2015). As noted in the opinion (FGE.208Rev1), the Panel considered
that a comparison with concurrent control is more relevant than a comparison with historical control
data, especially if the range of historical control data is broad as it is the case here.
The authors of the two articles actually consider like the CEF Panel that p-mentha-1,8-dien-7-al
induced an increase in DNA damage in the in vivo comet assay. The difference between EFSA and the
authors is that they consider the effect due to liver toxicity. However, in the same paper, the authors
noted that liver toxicity, at the top dose, does not interfere with the validity of the assay.
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